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ABSTRACT 
 
VEGF gene therapy is a promising alternative treatment method for patients with severe cardiovascular 
diseases. Pro-angiogenic growth factors involve theoretical risks, such as acceleration of pathological 
angiogenesis in tumour growth and retinopathy, inflammatory responses and tissue oedema that need to 
be carefully assessed. VEGF-A is the most commonly used growth factor in clinical gene therapy trials and 
its short-term safety has been investigated in several studies. However, there is limited data available 
regarding long-term effects and safety of VEGF gene therapy. 
In this work we investigated the safety and effects of VEGF gene transfer. Primary endpoints were to 
assess long-term safety of adenoviral (Ad) and plasmid/liposome (P/L) mediated VEGF-A gene therapy in 
the treatment of coronary artery disease (CAD) and peripheral artery disease (PAD) in patients not 
suitable for revascularization. In addition, we investigated the short-term safety and feasibility of the very 
first adenovirus mediated VEGF-DΔNΔC gene transfer performed by using transseptal puncture in no- 
option CAD patients. Secondary endpoint was to study long-term efficiency and effects of VEGF-A gene 
transfer in these patient groups. 
The incidence of cancer, retinopathy or diabetes did not increase significantly in AdVEGF-A or 
P/LVEGF-A groups compared to the control groups in 8- and 10-year follow-ups (CAD and PAD, 
respectively). Furthermore, there was no significant difference in mortality between the groups. In CAD 
patients, no statistically significant difference in working ability, exercise tolerance, or major cardiac 
events was seen between the groups. In PAD patients no difference in the number of amputations, 
vascular interventions, or exercise tolerance was detected between the treatment and control groups. 
In the short-term interim safety evaluation of VEGF-DΔNΔC gene transfer laboratory parameters, clinical 
examination and transthoracal echocardiography (TTE) as well as severe adverse events (SAE) were 
assessed. According to the results, transseptal puncture proved to be a feasible and well tolerated method 
to deliver gene into the left ventricular myocardium. No serious arrhythmias during or after the procedure 
were detected. Transient elevation in body temperature and inflammatory parameters were seen in both 
control and treatment groups. Minimal pericardial effusion was seen in a few patients in the treatment 
group. However, this was resolved spontaneously and required no further procedures. 
In conclusion, our studies suggest that local VEGF-A gene transfer for CAD and PAD is safe in long- 
term follow-up and does not increase the incidence of cancer, diabetes, or its complications. No difference 
in mortality, major cardiovascular events, or exercise tolerance was seen in either of the studies when 
compared to the control groups. Furthermore, VEGF-DΔNΔC gene therapy by using transseptal puncture 
route is feasible and well tolerated. 
 
National Library of Medical Classification: QU 560, WG 166 
Medical Subject Headings: Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor D; 
Gene Transfer Techniques; Genetic Therapy/adverse effects; Cardiovascular Diseases; Coronary Artery 
Disease/therapy; Peripheral Vascular Diseases/therapy; Follow-Up Studies; Neoplasms; Diabetic 
Retinopathy 
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TIIVISTELMÄ 
 
VEGF- geenihoito on lupaava uusi hoitomuoto vaikea-asteisia sydän- ja verisuonisairauksia sairastaville 
potilaille. Verisuonten kasvua edistäviin eli angiogeneettisiin kasvutekijöihin liittyy kuitenkin teoreettisia 
riskejä, kuten verisuonikasvun patologinen lisääntyminen pahanlaatuisissa kasvaimissa ja diabeettisessa 
silmänpohjasairaudessa/retinopatiassa. Lisäksi geenihoitoon liittyen on havaittu immunologisia reaktioita ja 
geenihoidolla hoidetun kohdekudosten turvotusta. VEGF-A on eniten käytetty verisuonten kasvutekijä 
kliinisissä tutkimuksissa ja sen turvallisuutta on tutkittu useissa lyhyen aikavälin seurantatutkimuksissa. 
Pitkäaikaisista vaikutuksista ja hoidon turvallisuudesta on kuitenkin vain vähän tutkimustietoa saatavilla. 
Tässä työssä ensisijainen tavoite oli selvittää virus (adenovirus, Ad)- ja rasvapartikkeli (plasmidi/liposomi, 
P/L)-välitteisen VEGF-A geenihoidon turvallisuutta sepelvaltimo- ja ääreisvaltimotautia (ASO) sairastavilla 
potilailla, joille muut hoitomuodot ovat riittämättömiä tai soveltumattomia. Toisena tavoitteena oli tutkia 
VEGF-A geenihoidon tehokkuutta ja pitkäaikaisvaikutuksia näissä potilasryhmissä. Lisäksi tutkimme toisen 
tyyppisen verisuonikasvutekijän eli VEGF-DΔNΔC -geenihoidon turvallisuutta ja hoitomenetelmän 
käytettävyyttä vaikea-asteista sepelvaltimotautia sairastavilla potilailla. Kyseessä oli ensimmäinen kliininen 
tutkimus kyseisellä geenillä.  
Kymmenen vuoden seurannassa ei havaittu merkitseviä eroja syövän, silmänpohjasairauden tai diabeteksen 
esiintyvyydessä geenihoidon saaneiden potilaiden ja kontrollihenkilöiden välillä. Kuolleisuudessa ei 
myöskään todettu tilastollista eroa ryhmien välillä sepelvaltimo- tai ASO-potilaiden kohdalla.  
Hoidon tehokkuutta mittaavassa tutkimuksessa VEGF-A geenihoitoa saaneilla potilailla ei todettu 
tilastollisesti merkittävää eroa rasituksen siedon, sydäntapahtumien tai työkykyisyyden suhteen hoito- ja 
kontrolliryhmien välillä. Samoin ASO-potilailla ei todettu merkittäviä eroavaisuuksia amputaatioiden, 
vaskulaaritoimenpiteiden tai fyysisen suorituskyvyn suhteen. 
VEGF-DΔNΔC tutkimukseen liittyvän välianalyysin tulokset osoittivat käytetyn geeninsiirtomenetelmän 
olevan käyttökelpoinen ja hyvin siedetty hoitomuoto vaikeassa sepelvaltimotaudissa. Vakavia rytmihäiriöitä 
ei todettu toimenpiteeseen liittyen. Ohimenevää lämmön ja tulehdusarvojen nousua todettiin yhtä paljon 
sekä geenihoitoa saaneilla että kontrollipotilailla. Lievää ja nopeasti ohimenevää sydänpussin nesteilyä 
todettiin yksittäisillä geenihoitoa saaneella potilaalla.  
Tutkimuksemme osoittavat paikallisen VEGF-A geenihoidon olevan pitkällä aikavälillä turvallinen 
hoitomuoto sepelvaltimo- ja ASO-tautia sairastavilla potilailla. Lisäksi uusi sydänlihaksen sisäinen VEGF-
DΔNΔC -geenihoito on käyttökelpoinen ja hyvin siedetty menetelmä vaikeaa sepelvaltimotautia sairastavilla 
potilailla, joille ei ole tarjolla muuta hoitovaihtoehtoa. 
 
 
 
 
Yleinen Suomalainen Asiasanasto: geeniterapia, sydän- ja verisuonitaudit, turvallisuus, seurantatutkimus, 
syöpätaudit, diabetes 
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1 Introduction 
 
 
Cardiovascular diseases are the leading cause of death and morbidity in developed 
countries. The incidence is also constantly increasing in developing countries. According 
to the World Health Organization’s statistics, 17,3 million people died of cardiovascular 
diseases in 2008 worldwide and the number is estimated to reach 23,3 million by the year 
2030 [WHO 2008]. 
Pharmacological therapy and revascularization offer an efficient treatment and improve 
the quality of life of patients with ischemic cardiovascular diseases. However, there are an 
increasing number of patients that do not benefit sufficiently from these treatment options 
and remain symptomatic despite maximal medication. Additionally, due to advanced 
disease and diffuse atherosclerotic plaques, or high risks for operations, revascularization 
may not be suitable [Andréll et al. 2011]. 
Gene therapy has been investigated as a novel treatment method for cardiovascular 
diseases. Vascular endothelial growth factor (VEGF) is a growth factor produced by 
endothelial cells to regulate angiogenesis and lymphangiogenesis. In adults, VEGF 
secretion is induced mostly by hypoxia. VEGF also induces pathological angiogenesis 
from pre-existing vessels. In embryo, VEGF regulates natural development of arteries, 
veins and lymphatic vessels. The members of VEGF family are the most selective 
activators of angiogenesis. VEGF-A has shown the fastest response to hypoxia and is 
therefore one of the most widely investigated growth factors in cardiovascular diseases. 
Furthermore, other growth factors such as Fibroblast growth factors (FGF) and Platelet 
derived growth factors (PDGF) have been studied as potential therapeutic agents [Zachary 
and Morgan 2011]. 
Gene therapy has shown promising results in preclinical studies. Substantial 
improvement in collateral vessel growth in animal models has been seen in multiple trials 
[Rissanen and Ylä-Herttuala 2007; Whitlock et al. 2004]. The results of clinical trials have 
been fairly modest, although some improvement, for instance, in myocardial perfusion has 
been detected [Hedman et al. 2003]. Replication deficient viral vectors have proven to be 
the most efficient in terms of gene transduction and expression [Giacca et al. 2012]. The 
risk of immunological responses is, however, higher compared to non-viral vectors. Non- 
viral vectors have a better safety profile and fewer adverse effects, but they have not 
reached the same efficiency in gene transfer as viral vectors [Wang et al. 2012]. 
In addition  to immunological  responses, there  are theoretical risks associated  with 
VEGF mediated gene therapy, such as tumour growth, induction of diabetic retinopathy, 
and  oedema  [Ylä-Herttuala  et  al.  2007].  Indeed,  VEGF  is  prominently  expressed  in 
2  
malignant tumours and enables the rapid and uncontrollable vessel growth inside the 
tumour. VEGF suppressing gene therapy has improved the prognosis of various types of 
cancers [Gatson et al. 2012] and reduced the progression of retinopathy [Davis et al. 2009]. 
Clinical cardiovascular VEGF trials have not shown increase in the incidence of cancer in 
short-term follow-ups. Also short-term safety aspects of VEGF-A are well known and no 
major safety concerns have been reported [Stewart et al. 2006; Hedman et al. 2003; 
Mäkinen et al. 2002]. However, only limited data of the long-term safety effects are 
available. 
The purpose of this work is to investigate the long-term safety aspects and efficiency of 
local VEGF-A gene therapy in the treatment of CAD and PAD patients. In addition, the 
short-term and procedural safety of novel VEGF-D∆N∆C therapy in no-option CAD patients 
is studied. A profound evaluation of safety is indispensable considering wider therapeutic 
use and contributes to the better understanding of long-term effects of gene therapy. 
3  
2 Literature review 
2.1 NORMAL DEVELOPMENT OF ARTERIES 
 
2.1.1 Vasculogenesis 
Vasculogenesis is defined as the physiological formation of vascular structures during 
embryonic development concerning the development of arteries, veins, and lymphatic 
vessels [Carmeliet and Jain 2011]. All blood and endothelial cells arise from embryonic 
mesenchymal tissue known as angioblasts. Angioblasts are differentiated into 
hemangioblasts, which further differentiate into two cell types, hematopoietic and 
endothelial precursor cells. Hematopoietic cells are the early form of all the blood cells 
whereas endothelial precursor cells differentiate into mature endothelial cells (EC) 
forming the vessel structure. A number of factors, such as VEGF, vascular endothelial 
growth factor receptor -2 (VEGFR 2), PDGFs, and FGFs are involved in different stages of 
the development by inducing the vessel growth. Some factors, such as VEGFR-1, act as 
stabilizers of the vessel growth [Carmeliet 2000]. 
 
 
2.1.2 Angiogenesis 
Angiogenesis is defined as vascular formation from already existing vessels. During 
embryonic development it is a normal phase of the vascular development. Vessels are 
dilated, extracellular matrix becomes looser, and permeability of vessel wall increases to 
enable ECs to migrate and proliferate. Eventually they sprout and form new vessel lumens 
[Conway et al. 2001]. 
In adults, physiological angiogenesis occurs only, for instance, during wound healing 
[Morgan and Nigam 2013] and thickening of endometrium [Rogers et al. 2009]. 
Pathological angiogenesis might occur as a reaction to hypoxia in an obstructed artery or 
as a result of mutations in a malignant tumour [Robbins and Cotran 2005]. 
When ECs are exposed to hypoxia, nitric oxide (NO) is released causing vasodilation as 
the first step of the process. This induces release of hypoxia-induced factors, such as 
VEGFs, FGFs, angiopoietin (Ang) -2, and chemokines. As a result, the vessel permeability 
is increased and intracellular junctions become loosened. Plasma proteins extravasate into 
the site and create a temporary support structure to enable activated ECs to migrate into 
the extracellular matrix (ECM) [Carmeliet 2000]. Ang-1 has a function as a stabilizer of the 
vessel during this process preventing excessive permeability and leakage through the 
vessel wall [Fagiani and Christofori 2013]. 
A large number of agents and factors are involved in the process. In addition to VEGFs, 
FGFs and VEGF-receptors, NOTCH-ligands, DLL4 and placental growth factor (PlGF) 
4  
amongst others are presented in the degradation of ECM, migration of ECs and 
development of new lumen with stabilized endothelial and pericyte layers [Carmeliet and 
Jain 2012]. However, these vessels lack smooth muscle cells (SMCs), which make them 
more fragile and less able to adjust to changes in blood flow than the vessels from which 
they sprout. Blood perfusion through the lumen is essential for the newly formed vessels 
and regression occurs if a constant blood flow fails to be maintained [Buschmann and 
Schaper 1999]. 
 
 
 
Figure 1 Angiogenesis. Reproduced by permission from Wolters Kluver Health, (Fam et al.), 
Copyright (2003). 
 
2.1.3 Arteriogenesis 
Arteriogenesis is the stage after angiogenesis when a layer of SMCs and pericytes 
developes around the newly formed endothelium. Arteriogenesis gives vessel its visco- 
elastic properties and is therefore essential for the proper function and survival of the 
vessel. It enables the vessel to maintain a stabilized structure under shear stress caused by 
blood flow [Helisch and Schaper 2010]. 
During embryonic development, SMCs of coronary arteries originate from atrial 
epicardium, and SMCs of larger arteries originate from neural stem cells. Formation of 
SMCs is regulated by a number of factors, such as genes of MEF2 and GATA families. 
Ang-1 and Tie2 stabilize the wall and induce sprouting and remodeling of the arteries. 
Transforming growth factor (TGF)-β1 and TGF-βR2 on the other hand inhibit the 
proliferation and migration of ECs. 
5  
In hypoxia-induced arteriogenesis, blood flow increases in collateral vessels 
surrounding the obstructed artery. This causes vessels to dilate and ECs to produce 
monokines and monocyte adhesion molecules. Monocytes migrate into the media layer, 
which triggers the production of FGFs, PDGFs and TGF-β1. As a result, SMC layer 
thickens and the collateral vessels strengthen and form mature arterial structure 
[Carmeliet 2000]. 
 
2.2 ATHEROSCLEROSIS 
 
Atherosclerosis is characterized by accumulation of fatty plaques inside the arterial wall 
causing inflammation and obliteration of the artery lumen. Due to a number of genetic 
and environmental risk factors, accumulation of excess cholesterol along with 
inflammatory cells in the artery wall cause lumen of the artery to diminish in diameter. 
This process is slow and happens usually over a course of several years or decades. As the 
size of the occlusion or stenosis reaches a point where a significant percentage of the artery 
lumen is obstructed, the tissues’ demand of oxygen exceeds the supply that can be 
delivered around the obstructed site. This leads to ischemia in the target tissue causing 
symptoms, such as angina pectoris in CAD and claudication in PAD. Development of 
atherosclerosis takes years to reach a clinically manifested state [Robbins and Cotran 
2005]. Genetic background is a risk factor for atherosclerosis, but environmental factors 
have a substantial role in the progression and prognosis of the disease. Smoking, obesity, 
dyslipidaemia, diabetes, hypertension, and age along with family history are known risk 
factors for atherosclerosis [Wilson et al. 1998;Khot et al. 2003]. The incidence of 
atherosclerosis is higher in men, since women with higher levels of estrogen hormone are 
better protected against it. However, the incidence in women increases after menopause 
[Matthews et al. 1998]. 
Due to these risk factors there is an imbalance in the amount of inflammatory agents 
and lipids in the coronary blood stream. Lipids, mainly low-density lipoprotein (LDL)- 
cholesterol, accumulate inside the intimal layer of the artery wall where they form fatty 
strikes as the early manifestation of atherosclerosis. Fatty strikes are seen as early as in 
adolescence and young adulthood in the coronary arteries [Ylä-Herttuala et al. 1987]. They 
consist mainly of T-cells and macrophages [Stary et al. 1994]. At the presence of persistent 
dyslipidaemia and accumulation of LDL inside the intima, elevated blood pressure, 
hyperglycaemia, and impaired function of adipose tissue due to obesity lead to oxidation 
of LDL and dysfunction of endothelial cells. This attracts inflammatory cells, such as 
macrophages, T-cells, cytokines and interleukins. Inflammatory cells migrate inside the 
intima layer where macrophages start phagocytosis of fatty cells and turn eventually into 
fat containing foam cells (Figure 2). This induces chronic inflammation and formation of 
atheroma inside the artery wall [Hansson 2005]. Over time, the atheroma grows resulting 
6  
in narrowing of the artery, i.e., stenosis. In some cases, atheroma remains inside the vessel 
wall growing towards the outside of the wall and thus may not cause a significant arterial 
stenosis and classic symptoms [Hackett et al. 1988]. A thin and fragile fibrotic cap covers 
the surface of the atheroma and is in high risk to erupt. Acute coronary syndrome (ACS), 
stroke or critical limb ischemia (CLI) may occur at the event of rupture of an 
atherosclerotic plaque, which causes the intimal core to burst into the arterial lumen. The 
vessel damage quickly triggers a coagulation cascade involving platelet and fibrin 
activation, which leads to partial or complete obstruction of the artery (Figure 3) [Libby 
and Theroux 2005]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Migration and activation of inflammation  in the  arterial wall. Reproduced with 
permission from (Hansson 2005), Copyright Massachusetts Med Society. 
7  
 
 
Figure 3 Atherosclerotic plaque rupture. Reprinted by permission from Macmillan Publisher Ltd: 
[NATURE] (Mackman), Copyright (2008). 
 
2.3 CORONARY ARTERY DISEASE 
 
2.3.1 General aspects 
CAD amongst other cardiovascular diseases is one of the most significant causes of 
morbidity and mortality around the world [Celermajer et al. 2012]. It is a condition where 
coronary arteries are obliterated or obstructed due to atherosclerosis causing decreased 
blood flow and insufficient oxygen supply to myocardium [Robbins and Cotran 2005]. As 
the myocardial oxygen demand increases during physical stress, exercise related 
symptoms are most commonly the first to appear. In a severe case, it might lead to acute 
plaque disruption and total obstruction of the artery causing myocardial infarction (MI) 
[Braunwald 2007]. Diagnosis of CAD is initially based on clinical symptoms supported by 
risk factor evaluation. Bicycle exercise test (BET), computed tomography of coronary 
arteries, myocardial perfusion scintigraphy, or coronary angiography can be used to 
confirm the diagnosis and evaluate the stage of the disease and directions of appropriate 
treatment [Fox et al. 2006]. 
The severity of symptoms can be assessed by Canadian Cardiovascular Society (CCS) 
classification. It is an international classification based on exercise tolerance helping to 
assess the severity of the disease and the decision of the treatment (Table 1). 
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Table 1 Canadian Cardiovascular Society (CCS) classification. Modified from Campeau 1976. 
 
Stage Symptoms 
CCS1 Ordinary physical activity does not cause angina, such as walking and 
climbing stairs. Angina with strenuous or rapid or prolonged exertion at work 
or recreation 
CCS2 Slight limitation of ordinary activity. Walking or climbing stairs rapidly, 
walking uphill, walking or stair climbing after meals or in cold, or in wind or in 
emotional stress, or only during the few hours after awakening. Walking more 
than two blocks on the level and climbing more than one flight of ordinary 
stairs at a normal pace and in normal conditions 
CCS3 Marked limitation of ordinary physical activity. Walking one or two blocks on 
the level and climbing one flight of stairs in normal conditions and at normal 
pace 
CCS4 Inability  to  carry  on  any  physical  activity  without  discomfort,  anginal 
syndrome may be present at rest 
 
 
 
2.3.2 Treatment 
Risk factor management 
Treatment of CAD varies depending on risk factors, severity of the disease and symptoms 
as well as concomitant diseases. Managing the risk factors is the foundation of treatment 
in both primary and secondary prevention of CAD. Cessation of smoking, good control of 
blood pressure, cholesterol and blood glucose levels have a key role in successful 
treatment. Obeying dietary guidelines and adequate amount of physical exercise are an 
essential part of successful treatment and primary prevention, but pharmacological 
therapy is often required to enhance the effect in particular in the secondary prevention 
[Fox et al. 2006]. 
 
 
Pharmacological therapy 
According to the European Society of Cardiology (ESC) guidelines, antiplatelet therapy is 
recommended generally to all patients with diagnosed ischemic heart disease. 
Acetylsalisylic acid (ASA) is prescribed for most patients. However, they are not suitable 
for patients with a high risk of bleeding complications *Antithrombotic Trialists’ 
Collaboration 2002]. In addition, clopidogrel and ASA prevent stent thrombosis and 
restenosis after percutaneous coronary intervention (PCI) and stenting [Steinhubl et al. 
2002]. Also, the newer antithrombotic agents, prasugrel and ticagrelor, have recently 
shown to be more efficient in prevention of new cardiac events after PCI compared to 
clopidogrel [Clemmens et al. 2013]. Beta-blockers have been shown to reduce mortality in 
secondary prevention in CAD patients after MI. In addition, they help to lower blood 
pressure and alleviate symptoms [Freemantle et al. 2002]. However, the role of beta- 
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blockers has been recently challenged. In a trial that included over 44 708 patients, the use 
of beta-blockers did not reduce the risk of cardiovascular events [Bangalore et al. 2013]. 
Statins are the most commonly used lipid-lowering drugs and have been proven to 
efficiently improve prognosis in both primary and secondary prevention [Grundy et al. 
2004]. Short or long-acting nitro glycerines alleviate angina symptoms through transient 
dilation of vessels and reduced diastolic filling of the heart and are used sporadically or 
regularly in symptomatic patients. However, their use does not have effect on prognosis 
[Fox et al. 2006]. Calcium channel blockers are efficient in lowering blood pressure and 
reduce angina symptoms. Additionally they have shown proof of improved prognosis in 
some CAD patients [Costanzo et al. 2009]. Hyperglycaemia increases the risk of coronary 
events. In a recent study, patients with type-2 diabetes or impaired fasting glucose had an 
increased risk of sudden cardiac death compared to healthy controls. Thus, management 
of diabetes with oral and/or insulin treatment is crucial [Laukkanen et al. 2012]. 
 
 
Exercise training 
In addition to pharmacological therapy, exercise training has been shown to reduce 
mortality and angina symptoms in CAD patients through reduction of risk factors and 
improvement of endothelial function [Wienbergen and Hambrecht 2013]. 
 
Revascularization 
In case of inadequate response to pharmacological therapy or ACS, invasive 
revascularization is required. PCI is defined as a management of coronary artery occlusion 
by any of various catheter-based techniques, such as percutaneous transluminal coronary 
angioplasty, atherectomy, angioplasty using the excimer laser, and implementation of 
coronary stents and related devices [Smith et al. 2001]. PCI was first introduced in 1977 
and has since then become the most common invasive treatment method over coronary- 
artery bypass grafting (CABG). It is especially suitable for patients with one or two vessel 
disease and it has  significantly fewer risks  compared to CABG  [Serruys  et al. 2009]. 
Stenting has been shown to prevent restenosis compared to sole balloon angioplasty [Al 
Suwaidi et al. 2004]. Furthermore, newer drug-eluting stents appear to prevent in-stent 
restenosis more efficiently compared to bare metallic stents in some patient groups [Park 
et al. 2005; Sousa et al. 2003]. Equally drug-eluting balloons have proven effective in 
patients with challenging anatomy of coronaries or diffuse calcification [Waksman et al. 
2009]. The overall risk of death in a routine procedure is estimated 0.3-1% [Fox et al. 2006]. 
Common complications are procedure related vascular injuries, bleeding complications 
and stent thrombosis [Piper et al. 2003; Cheneau et al. 2003]. 
10  
CABG is the oldest method of revascularization. It is an open heart operation where 
patient’s own veins, usually the saphenous vein, are used as grafts to conduct blood flow 
around obstructed coronaries to preserve oxygen supply to the hypoxic myocardium 
[Sabiston and Spencer 2005]. Despite the improved PCI techniques, CABG is still the 
recommended treatment for patients with a 3-vessel disease or in case of stenosis of the 
left main coronary artery. It has been shown to reduce 1-year mortality in these groups of 
patients compared to PCI [Serruys et al. 2009]. Common complications related to CABG 
are postoperative bleeding, renal dysfunction, arrhythmias, and wound infections among 
others. Concomitant diseases may also increase the risk of complications. The overall 
operative mortality is estimated 3% [Sabiston and Spencer 2005]. 
 
 
Neurostimulation 
Neurostimulation therapy is used in patients with refractory angina when maximal 
medical therapy and revascularization options are either insufficient or contraindicated. 
There are two forms of stimulation being used: transcutaneous electrical nerve stimulation 
(TENS) and spinal cord stimulation (SCS). The effect of neurostimulation is assumed to be 
based on the gate theory of pain, where the stimulation of pain is masked by a 
counterstimulus [Murray et al. 2000]. Other theories to explain the pain reducing effect, 
such as release of endogenous endorphins and increase in coronary blood flow, have been 
presented [Chauhan et al. 1994; Eliasson et al. 1998]. 
Neurostimulation is also suggested to reduce ischemia through prevention of distress 
and activation of sympathetic nervous system followed by the sensation of ischemic pain. 
This in turn worsens the ischemia and symptoms. Alleviation of initial pain could thus 
prevent this cycle [de Jongste et al. 1994]. Pain is essentially a warning signal and there has 
been a concern whether neurostimulation masks this signal too efficiently in case of a 
threatening infarction. However, clinical trials have not supported this hypothesis and 
neurostimulation treatment has proved to be a safe treatment option [Hautvast et al. 1998; 
Sanderson et al. 1994]. 
 
 
2.4 PERIPHERAL ARTERY DISEASE 
 
2.4.1. General aspects 
PAD is characterized by occlusions and impairment of blood supply to the upper or lower 
extremities. This can be caused by embolism, thrombosis or vasculitis among others, but 
the most common cause is atherosclerotic lesions. PAD along with CAD and 
cerebrovascular disease is one of the most important manifestations of cardiovascular 
diseases [Braunwald 2007]. Risk factors are mainly the same as with other cardiovascular 
diseases,    including    age,    diabetes,    hypertension,    hypercholesterolemia,    genetic 
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background, and smoking [Tendera et al. 2011]. However, smoking seems to have a 
particular role in pathogenesis of PAD compared to CAD, which makes it a remarkable 
single risk factor [Fowkes et al. 2000; Ingolfsson et al. 1994]. The incidence of PAD 
increases significantly after the age of 50 and is higher in men than in women [Kroger et al. 
2006]. 
PAD can be classified into different categories based on the severity of symptoms and 
other clinical manifestations. The Fontaine classification was initially presented in 1954 
and is still widely used in clinical practice (Table 2) [Fontaine et al. 1954]. Additionally 
Rutherford’s classification is used alongside *Tendera et al 2011+. Other, more objective 
means measuring hemodynamic functions, such as ankle-brachial index (ABI) and 
transcutaneous oxygen pressure (TcOP2), have been introduced [Aronow 2012]. Magnetic 
resonance angiography (MRA), computed tomography angiography (CTA), and in some 
cases ultrasound and treadmill exercise tests are equally used in diagnostics [Tendera et al. 
2011]. 
Intermittent claudication is usually the first symptom of PAD. At a progressed stage it 
might lead to CLI in which case the distal perfusion pressure and nutrient blood flow to 
the diseased limb are severely disturbed by macrovascular lesions. Rest pain, chronic 
wounds and/or gangrene are present at this stage [Becker et al. 2011]. Acute limb ischemia 
(ALI) is characterized by rapid onset and progression of ischemic symptoms and can be 
caused by acute thrombus or embolus. Emergency revascularization is often needed 
[Tendera et al. 2011]. 
 
Table 2 Fontaine classification. Modified from Tendera et al. 2011. 
 
Stage Symptoms 
Stage I Asymptomatic 
Stage IIa Mild claudication 
Stage III Ischaemia rest pain 
Stage IV Ulceration or gangrene 
 
2.4.2 Treatment 
Risk factor management 
Proper management of risk factors is the foundation of the treatment in patients with 
diagnosed PAD. Lowering high blood pressure and cholesterol as well as high blood 
glucose are an essential part of the treatment [Mancia et al. 2009; Collins et al. 2003; Jude et 
al. 2010]. Smoking has been shown to be the most important individual risk factor for PAD 
[Diehm et al. 2011]. Therefore cessation of smoking has a substantial impact on the 
outcome of clinical symptoms such as claudication and peripheral ulcers. Current or 
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previous smoking increases the risk of PAD in lower extremities [Ness et al. 2000; Tendera 
et al 2011]. 
 
Pharmacological therapy 
Anti-platelet medication is part of the standard treatment in all PAD patients. ASA is most 
commonly used and reduces the risk of cardiovascular events and mortality. In addition, 
clopidogrel reduces the risk of adverse events. However, anti-platelet treatment has not 
been shown to significantly affect the walking distance [Momsen et al. 2009]. Use of beta- 
blockers does not have a negative outcome regarding claudication and is indicated in the 
presence of simultaneous CAD [Poldermans et al. 2009]. 
 
 
Exercise training 
Regular walking exercise has been proved to reduce intermittent claudication symptoms 
and slow progression of the disease [Bendemacher et al. 2006]. Set exercise treatment 
(SET) improved the exercise tolerance and walking distance by 50-200% [Watson et al. 
2008]. However, this form of treatment is not suitable for patients with CLI since it might 
worsen already existing wound lesions or gangrenes [Diehm et al. 2011]. 
 
 
Revascularization 
Revascularization is considered in case of CLI, ALI or insufficient response to medical 
therapy in patients with intermittent claudication. Endovascular treatment is less invasive 
compared to surgery and thus makes revascularization an option to a larger number of 
patients [Tendera et al. 2011]. In addition, mortality and risk of complications are lower 
compared to surgery and therefore percutaneous transluminal angioplasty (PTA) is 
commonly the primary revascularization option [Weinberg et al. 2011].  Drug-eluting 
stents and balloons are equally used in PTA to reduce the risk of restenosis [Buechel et al. 
2012]. Bypass surgery or endarterectomy are considered in case of diffuse and advanced 
disease. Surgical options also offer more sustainable results and a longer lasting 
conservation of blood circulation [Tendera et al. 2011]. 
Amputation is the final surgical option in case of irreversible ischemia and necrosis and 
if other forms of treatment are unsuitable or insufficient. Prognosis with amputated 
patients is generally poor and a two-year mortality rate after below-knee amputation is up 
to 30% [Norgren et al. 2007]. 
 
 
Neurostimulation 
Neurostimulation is not as commonly used in treatment of PAD as it is in patients with 
angina pectoris, although it is indicated as a treatment of PAD related claudication and 
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chronic pain of extremities [Rokyta and Fricová 2012]. Additionally, SCS has been 
successfully used in treatment of Buerger’s disease related claudication, which is a chronic 
vascular inflammatory disease causing similar ischemic symptoms and outcomes as PAD. 
Patients in the case report gained long-term benefit from the treatment [Vasquer Quiles et 
al. 2009]. 
 
2.5 GENE THERAPY 
 
 
2.5.1 Vectors 
Viral vectors 
Growth factors used in gene therapy cannot be transferred into the target cell without an 
efficient and safe delivery vector. A vector is required for the gene to pass the cell 
membrane and for successful expression of the transgene. Vectors used in gene therapy 
can be divided into two main categories, viral and non-viral vectors. Viruses are the most 
commonly used vectors due to their natural ability to penetrate and infect cells. This 
property also makes them more efficient in terms of transduction and leads to a higher 
gene expression compared to non-viral vectors [Giacca and Zacchigna 2012; Wang et al. 
2012]. 
Replication deficient adenoviruses are the most widely used gene delivery method of 
all the viral vectors in preclinical and clinical trials [Patel et al. 1999; Whitlock et al. 2004]. 
Over a hundred different types of adenoviruses are known to date and they are common 
pathogens causing infections of respiratory and gastrointestinal tract [Cupelli and Stehle 
2011]. Adenoviruses are DNA viruses and their benefits as gene therapy vectors are 
naturally high transduction efficiency to non-replicating cells and high gene expression. 
Adenoviruses have a theoretical ability to integrate into the host genome and thus cause 
potential mutagenesis. However, probability of such integration has been considered low 
[Harui et al. 1999]. First adenoviruses used in gene therapy were engineered to be 
replication deficient by deleting certain parts of its genome (E1 and E3). However, sections 
of the genome capable of triggering immune responses and theoretically mutagenesis in 
host cell remained [Danthinne and Imperiale 2000]. These properties caused safety 
concerns. In second and third generation adenoviral vectors inflammation triggering 
properties have been targeted [Giacca et al. 2012]. These vectors are often referred to as 
“gutless”, since the genome is replaced with the DNA of the therapeutic agent and viral 
genome does not become expressed. This reduces the risk and severity of host immune 
response, but the viral capsule alone is capable of triggering inflammation and thus the 
risk has not been entirely eliminated. However, safety has improved since the introduction 
of these third generation vectors [Alba et al. 2005; Räty et al. 2008]. Adenoviruses have also 
14  
other applications in biomedicine and in addition to gene therapy their use as oncolytic 
agents is increasing and promising results have been achieved [Ganly et al. 2000; Cerullo 
et al. 2012]. 
Retroviruses were the first vectors used in gene therapy. Retrovirus is a ribonucleic acid 
(RNA) virus, which after transduction into the host cell, is reversed into DNA and 
becomes integrated as part of the host genome [Gaffney et al. 2007]. Retroviruses very 
efficiently transduce proliferating cells, however, their ability to enter non-mitotic cells, 
such as cardiac myocytes or ECs is poor and therefore they are not particularly useful in 
cardiovascular gene therapy. Although retroviruses have been engineered and made 
replication deficient [Wu et al. 2005], a potential risk of mutagenesis into a replication 
capable virus, and carsinogenesis due to its integration into the host genome, cannot be 
excluded [Manilla et al. 2005]. 
Lentiviruses are a subgroup of retroviruses and use similar mechanism to transduce 
target cells as retroviruses. They are based on human immunodeficiency (HI)-1 virus and 
differ from other retroviruses with their ability to transduce non-replicating cells [Giacca 
et al. 2012]. Nevertheless, they share the same risks and problems with other forms of 
retroviruses. Due to advancements in biotechnology and vector engineering, safety profile 
of lentiviruses has improved and third generation lentiviruses currently used in trials have 
demonstrated a better safety profile regarding immune responses and potential 
mutagenesis. They are used in preclinical and clinical trials for a variety of genetic 
disorders, such as sickle cell anaemia *Pestina et al. 2009+, β-thalassemia [Cavazzana-Calvo 
et al. 2010; Miccio et al. 2008] and adrenoleukodystrophy (ALD) [Cartier et al. 2009]. 
Adenoassociated viral (AAV) vectors belong to the family of parvoviridae –viruses and 
they are the smallest viruses used in gene therapy. Currently 12 different serotypes of 
AAV have been identified and characterized. AAV2 serotype is the most frequently used 
in gene therapy [Giacca and Zacchigna 2012]. AAVs bind to several different receptors, 
such as heparin sulphate proteoglycans (HSPGs), avß5 integrin and fibroblast growth 
factor receptor (FGFR)-1 [Zentilin and Giacca 2008]. Advances made in vector engineering 
in the past few years have significantly improved AAVs properties as a delivery vector 
and the latest generation of AAVs have a number of favourable features. AAVs have a 
simple structure and no viral proteins are expressed in the target cells. In addition, viral 
genome does not integrate in the host genome. Thus, the risk of immunological responses 
and harmful mutations is reduced. AAVs also seem to cause long-term gene expression in 
the target cells [Büning et al. 2003; Ortolano et al. 2012;]. Due to these properties AAVs 
have become popular vectors in clinical trials. Some trials have achieved successful results 
in the treatment of e.g. heart failure, haemophilia B and hereditary blindness [Bainbridge 
et al. 2008; Giacca and Baker 2011; Kay et al. 2000]. 
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A number of other viruses have been investigated as potential gene delivery mediators. 
For instance, baculoviruses  and  herpes  simplex virus  (HSV)  have been  used in gene 
therapy. The former in therapy targeted to the heart, liver and brain [Heikura et al. 2012; 
Hoare et al. 2005; Lehtolainen et al. 2003] and the latter in particular for cancer and 
diseases of the central nervous system [Marconi et al. 2008]. 
 
 
Non-viral vectors 
The use of non-viral vectors in gene delivery has many potential advantages compared to 
viral vectors. They are cheaper and easier to produce. More importantly, they do not 
trigger the host immune system or dispose a similar risk of mutagenesis compared to viral 
vectors, and are thus safer to use. Non-viral vectors can additionally be administered 
repeatedly. Despite of these advantages, the main obstacle for their more extensive use is 
lack of efficiency. In terms of transfection efficiency and gene expression time viruses are 
superior to non-viral vectors [Wang et al. 2012]. Plasmids are commonly used non-viral 
vectors in gene therapy [Hedman et al. 2003; Kastrup et al. 2005; Sarkar et al. 2001], but the 
gene expression time has mostly been limited to 1-2 weeks [Ylä-Herttuala and Alitalo 
2003]. They are naturally hydrophilic, which complicates their transduction through 
lipophilic cell membranes. Studies have also indicated that plasmid vectors injected 
directly into the nucleus of non-dividing cells cause high gene expression. However, if the 
delivery only reached cytoplasm, the gene expression turned out to be very weak 
[Capecchi 1980; Mirzayans et al. 1992]. This is caused by degradation of free DNA bound 
to plasmid vector by cytoplasmic nucleases after phagocytosis [Dean et al. 2005]. Further 
studies have shown only 1-15% of the DNA to reach the nucleus and eventually express 
the gene [Tachibana et al. 2001]. This phenomenon significantly limits the use of plasmid 
vector in non-dividing cells. 
For dividing cells the transduction might be more efficient since the structure of the 
nucleus brakes and divides during mitosis allowing easier entry for DNA into the nucleus. 
To solve these problems, different enhancers, such as liposomes and chitosan have been 
used to add a lipophilic component to the vector and thus facilitate the transduction 
through the cell membrane [Al-Dosari and Gao 2009]. In addition, other means to enhance 
transduction, such as affecting cell membrane photochemically or with ultrasound 
[Kloeckner et al. 2004; Taniyama et al. 2001] and packaging vectors in multifunctional, 
protective “envelopes” *Nakamura et al. 2006+, have been investigated. 
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2.5.2 VEGF Family 
VEGF-A 
VEGF-A is the best known and the most investigated member of the VEGF family. It was 
cloned for the first time in 1989 [Leung et al. 1989] and since then has been used in 
numerous preclinical and clinical gene therapy trials. VEGF-A has seven isoforms: 121, 
145, 148, 165, 183, 189 and 206. However, three of these isoforms, 121, 165 and 189 code 
99% of all the expressed growth factors and thus have been the main focus of interest in 
gene therapy [Whitlock et al. 2004]. VEGF-A has two main receptors, VEGFR-1 and 
VEGFR-2. In addition, isoforms 165 and 145 are bound by neuropilin-1 and 2. VEGFR-2 is 
the most important signalling receptor and in angiogenesis, where as VEGFR-1 may also 
inhibit angiogenesis [Ylä-Herttuala et al. 2007]. 
VEGF-A is expressed by ECs as a response to tissue ischemia. It is expressed in all 
tissues during vascular  formation. Along with other  growth factors and regulators it 
induces permeability, migration and proliferation of ECs and is the most important single 
growth factor in angiogenesis. VEGF-A is also known to participate in vascular 
homeostasis and maintenance of stabilized vascular structure [Zachary et al. 2000]. VEGF- 
A knockout mice are embryonic lethal [Karkkainen et al. 2004] and deletion of endothelial 
VEGF-A in healthy mice caused systemic endothelial apoptosis and degradation leading 
in severe haemorrhage, intestinal perforations and premature death [Lee et al. 2007]. This 
further emphasizes the significance of VEGF for healthy functioning vasculature. It has 
been suggested that VEGF-A is involved in the development of atherosclerosis in animal 
models due to its overexpression in atherosclerotic arterial wall through promotion of pro- 
inflammatory agents and pathological function of ECs and SMCs [Inoue et al. 1998;Bräsen 
et al. 2001]. However, no evidence regarding progression of atherosclerotic plaques has 
been seen in a large number of VEGF-A trials [Laitinen et al. 1998;Henry et al. 
2003;Kastrup et al. 2005]. Thus this question remains unanswered, but it seems that the 
presence of VEGF-A is rather a consequence of hypoxia than the initial cause of the disease 
process. 
In preclinical trials isoforms 121 and 165 have shown the most promising results in 
formation of new collateral vessels and increase of tissue perfusion [Rissanen et al. 2005; 
Perrin et al. 2004; Mack et al. 1998; Magovern et al. 1997]. A clinical trial showed VEGF165 to 
induce collateral circulation and perfusion in patients with critical limb ischemia 
[Baumgartner et al. 1998]. Furthermore, VEGF165-mediated intracoronary gene therapy 
improved myocardial perfusion in CAD patients [Hedman et al. 2003; Losordo DW 1998]. 
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VEGF-B 
VEGF-B is present in angiogenesis, but in lower quantities than VEGF-A, and has also 
been shown to be expressed faster in hypoxic tissue. It is expressed in heart, skeletal 
muscle and brown adipose tissue [Robbins and Cotran 2005]. VEGF-B has been considered 
less useful for proangiogenic therapy and has not gained as great interest in research as 
VEGF-A and some other growth factors [Ylä-Herttuala et al. 2007]. VEGF-B knockout mice 
have no major abnormalities [Li et al. 2009]. However, VEGF-B mediated gene therapy 
was shown to improve myocardial function in pigs [Lähteenvuo et al. 2009] and in mice 
with heart failure through angiogenesis, cell proliferation and inhibition of apoptosis 
[Huusko et al. 2012]. In addition, VEGF-B has recently been discovered to have an 
important role in regulation of trans-endothelial transport of circulating fatty acids into 
cardiac and skeletal muscles [Hagberg et al. 2010]. Furthermore, reduction in VEGF-B 
signalling increased insulin sensitivity, preserved pancreatic function and had  a 
favourable outcome on lipid profile in mouse models [Hagberg et al. 2012]. 
 
 
VEGF-C 
VEGF-C is mainly expressed during lymphangiogenesis, but also has a role in 
angiogenesis. Equally it is present during vasculogenesis and development of lymphatic 
vessels in embryo. VEGF-C knockout mice are embryonic lethal [Karkkainen et al. 2004]. 
Significance of VEGF-C in therapeutic angiogenesis has been considered less clear and 
therefore it has not been studied as vigorously as other growth factors for proangiogenic 
gene therapy. VEGF-C mediated gene therapy has proven to be efficient in vivo in 
formation of new lymphatic vessels and treatment of oedema caused by malfunctioning 
lymphatic drainage [Saaristo et al. 2002; Enholm et al. 2001]. Similar to VEGF-A, VEGF-C 
has been suggested to have a role in maintenance and progression of atherosclerotic 
inflammation. VEGF-C was discovered to be present in arterial intima and macrophages in 
atheroma plaques of human coronary arteries [Rutanen et al. 2005; Nakano et al. 2005]. 
However, progression of atheroma  lesions has not been confirmed  by other VEGF-C 
studies [Hiltunen et al. 2000; Anisimov et al. 2009]. Furthermore, CD11b(+)- derived 
VEGF-C was found to enhance tissue perfusion in ischemic murine hind limb [Kuwahara 
et al. 2012] and to prevent restenosis [Rutanen et al. 2005]. VEGF-C binds to three different 
receptors, VEGFR-2, VEGFR-3 and neuropilin-2 [Ylä-Herttuala et al. 2007]. 
 
 
VEGF-D 
Both VEGF-D and VEGF-C function as a lymphangiogenic growth factors and they share 
the same receptors,VEGFR-2 and VEGFR-3 [Ylä-Herttuala et al. 2007]. VEGF-D knockout 
mice have no major abnormalities [Karkkainen et al. 2004]. Two different isoforms of 
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VEGF-D have been identified, a full-length and a shorter, mature (∆N∆C) form. VEGF-D is 
proteolytically activated and does not require hypoxia for induction or regulation. In 
particular the mature form of VEGF-D, also referred as VEGF-D∆N∆C, has a less aggressive 
but longer and more sustainable expression compared to other VEGFs [Zachary and 
Morgan 2011; Rutanen et al. 2004]. The length of gene expression seems to be crucial for 
the efficiency, and thus VEGF-D∆N∆C is expected to show improved results regarding 
collateral vessel growth and tissue perfusion. Various preclinical studies have 
demonstrated encouraging results. Adenoviral VEGF-D∆N∆C gene transfer induces 
microvessel growth in a rabbit hindlimb model where as the full-length VEGF-D was 
detected mostly to regulate lymphangiogenesis [Rissanen et al. 2003]. Another VEGF- 
D∆N∆C study using baculovirus as a vector equally showed evidence of increased vascular 
perfusion in rabbits skeletal muscle [Heikura et al. 2012]. In porcine heart adenoviral 
VEGF-D∆N∆C gene transfer increased myocardial perfusion and induced angiogenesis 
compared to VEGF-A165 [Rutanen et al. 2004]. In addition, increased vessel formation was 
detected in diabetic rabbit skeletal muscles [Roy et al. 2010]. 
According to studies performed in vivo, VEGF-D seems to have an important role in 
cancer metastasising via lymphatic circulation through enhancement of 
lymphangiogenesis and regulation of prostaglandin production [Karnezis et al. 2012]. 
Furthermore, downregulation of VEGF-D and VEGF-C production and 
lymphangiogenesis through inhibition of VEGR-3 prevented lymph node metastasis in 
mouse models [He et al. 2002; Lin et al. 2005]. 
 
 
PlGF 
PlGF is a member of the VEGF family and it is expressed in placenta, lungs, and thyroid 
gland. It has three isoforms, 131, 152, and 203. 131 and 203 are soluble whereas 152 binds 
to heparin sulfate. PlGF is involved in hypoxia-induced angiogenesis by stimulating 
production and migration of macrophages. Activation of the immune system promotes 
release and production of other angiogenic factors. In addition PlGF activates proliferation 
and migration of ECs and stimulates fibroblasts as well as other mural cells in the vessel 
wall [Ylä-herttuala et al. 2007]. Furthermore, there is evidence, that PlGF is involved in 
pathogenesis of diseases affecting the nervous system [Chaballe et al. 2011]. PlGF has 
many functions in normal vascular development. However, studies in vivo have shown 
PlGF to be redundant in many of these processes and PlGF knockout mice show no 
abnormalities or disturbance in the development of vasculature and later homeostatic 
functions. Further studies suggest that the role of PlGF is emphasised during pathological 
angiogenesis. PlGF has been shown to be overexpressed in pathological processes in heart, 
retina,  skeletal  muscle,  wound  and  tissue  damage  healing,  tumour  growth,  and 
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haematological malignancies. It has been a target of investigation especially in anti- 
angiogenic cancer research [Dewerchin et al. 2012]. 
 
2.5.3 Other growth factors 
PDGF 
PDGF is a growth factor that consists of two protein chains, A and B. They can form three 
different isomers, AA, BB and AB. PDGF C and D have also been discovered. However, 
their significance is yet to be determined [Li et al. 2003]. PDGFs are involved in growth of 
connective tissue cells such as fibroblasts and SMCs. PDGFs bind to receptors PDGFR α 
and β. PDGF is restored in α-granules of thrombocytes and is released during 
thrombocyte activity. Macrophages, ECs, SMCs, and tumour cells can also express PDGF. 
Expression is followed by proliferation of SMCs, fibroblasts and monocytes, which 
enhances angiogenesis [Chen et al. 2012]. PDGF- β prolonged the angiogenic effect in 
combination with VEGF-A in rabbit hind limb [Korpisalo et al. 2008]. 
 
 
FGF 
The family of FGFs has multiple members.  To date 22 different members have been 
discovered. In general they are involved in tissue growth, proliferation, and migration. 
They act as an inducer in wound healing and tissue repair through activation of 
macrophages, fibroblasts, and ECs. In embryo, FGFs have a role in the development of 
skeletal muscles, lungs, blood cells, and bone marrow [Beenken and Mohammadi 2009]. 
FGF-1 and FGF-2 affect ECs and they have been shown to be involved as pro-angiogenic 
agents [Ware and Simons 1997; Iwakura et al. 2000]. Activation of a particular gene, PR39, 
is known to be a trigger for overexpression of VEGF and FGF-2. This has been proven to 
increase myocardial perfusion in porcine model [Post et al. 2006]. Other FGF members of 
interest are FGF-4 and FGF-5, which also have shown to improve perfusion and increase 
left ventricular (LV) function [Rissanen et al. 2003;]. 
 
 
HGF 
Hepatocyte growth factor (HGF) originates from mesenchymal cells and it has a mitogenic 
effect on most epithelial cells such as hepatocytes and epithelial cells of skin and lungs. It 
binds to tyrosine kinase receptors and thus promotes proliferation and migration of the 
cells [Lavu et al. 2011]. During embryonic development, HGF acts as a morphogenic agent 
and promotes scattering and migration of cells [Robbins and Cotran 2005]. HGF gene 
therapy has been shown to induce angiogenesis [Morishita et al. 2004] as well as decreased 
scar formation and improved myocardial function after MI in animal models [Li et al. 
2003; Azuma et al. 2006]. 
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IGF 
Insulin-like growth factor (IGF) is a group of growth factors, which consists of three 
members, IGF-I, IGF-II, and insulin. These three ligands have partly similar peptide 
sequences and basic molecular structures. In addition to metabolic functions, IGF-I and 
IGF-II are also known to have cell proliferation promoting activities [Juul 2003]. IGFs have 
two main receptors: insulin receptor (IR) and IGF- I receptor (IGF-IR). Both are tyrosine 
kinase receptors and as names suggest, insulin binds to IR and IGF-I and IGF-II to IGF-IR 
[LeRoith et al. 1995]. In embryo, IGF-I is assumed to have a role in fetal growth and, along 
with growth hormone (GH), regulation of placental amino acid transport from mother to 
fetus. Deletion of IGF-I has shown to result in small size of the fetus in animal models [Liu 
et al. 1993]. Levels of IGF-I have been shown to increase as pregnancy advances and 
premature infants were detected to represent with lower levels of IGF-I [Leger et al. 1996]. 
IGF-I induces collateral vessel growth and therefore higher level of serum IGF-1 has been 
shown to be related to better survival in CAD patients after acute MI [Lee et al. 1999]. IGFs 
are involved in cell proliferation and therefore there has been evidence of connection 
between high circulating levels of IGF-I, IGF-II and cancer risk [Weroha and Haluska 2012; 
Harman et al. 2000; Kaaks et al. 2002]. Studies have suggested patients with GH deficiency 
and low IGF-I level to have a diminished overall risk of cancer [Erfurth et al. 2001]. In 
addition, IGFs have been shown to have a role in a large variety of other diseases affecting, 
for instance, liver and thyroid gland [Juul 2003]. 
 
 
2.6 CLINICAL VEGF TRIALS 
 
 
2.6.1 Coronary artery disease 
Some of the first nonrandomized VEGF-A trials of cardiovascular diseases used 
recombinant VEGF-A165 protein (RhVEGF-A165) as an angiogenic growth factor. Previous 
preclinical studies had showed promising results regarding efficiency [Harada et al. 1994]. 
A clinical trial with 15 patients reported dose-dependent improvement in myocardial 
perfusion and a good safety profile at lower protein dosages. The main safety issue was 
hypotension, which occurred at higher VEGF-A concentrations [Hendel et al. 2000]. 
The VIVA trial was a randomized phase II trial, using intracoronary RhVEGF-A165 with 
adenoviral vector as a study drug. There was no difference in exercise tolerance or angina 
symptoms between the treatment and placebo groups at 2-month follow-up. However, a 
statistically significant improvement in the treatment group regarding angina symptoms 
was detected at 4-month follow-up [Henry et al. 2003]. The results from these trials were 
considered discouraging and to date no further clinical trials using recombinant VEGF-A 
have been performed. 
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One of the first nonrandomized, phase I studies to use VEGF-A165 gene transfer in no 
option CAD patients was performed by Losordo et al. in 1998 via minithoracotomy. The 
procedure was performed on five patients using adenovirus as a delivery vector. The 
treatment appeared safe and all patients experienced relief in angina symptoms and 
improvement in myocardial perfusion was detected [Losordo et al. 1998]. Rosengart et al. 
investigated the effects of adenoviral VEGF-A121 gene therapy in a nonrandomized study 
that recruited 21 CAD patients. 15 of the patients received VEGF-A121 as an adjunct to 
CABG and six patients received the gene through minithoracotomy. No serious adverse 
events were reported during a 6-month follow-up. In addition, improvement in exercise 
tolerance and reduction of angina symptoms were reported [Rosengart et al. 1999]. A long- 
term safety follow-up of the patient cohort was recently published. The results showed no 
significant difference in mortality, the incidence of cancer or retinopathy  in 11,8-year 
follow-up [Rosengart et al. 2013]. 
Several randomized, phase II and III clinical trials using VEGF-A gene as a therapeutic 
agent for patients with advanced CAD have been conducted (Table 3). The Kuopio 
Angiogenesis Trial (KAT) recruited a total of 103 patients divided into three groups, two 
of which received intracoronary VEGF-A165 gene transfer either with adenoviral or 
plasmid/liposome vector and the third, control group received ringer’s lactate. Patients 
were followed up to one year. A significant improvement in myocardial perfusion was 
detected in AdVEGF-A165 group compared to p/lVEGF-A165 and control groups. In 
addition, gene transfer was reported to be well tolerated and feasible. Mild, transient 
elevation in infection parameters and body temperatures were seen in the advVEGF-A165 
group [Laitinen et al. 2000; Hedman et al. 2003]. 
In the NOVA trial, 17 patients were randomized 2:1 to treatment and control groups. 
The treatment group received intramyocardial injections of VEGF-A121 with adenoviral 
vector. In a one-year follow-up treatment proved to be safe, but no significant 
improvement in exercise tolerance or symptoms were detected between the groups. The 
number of study the patients was aimed to be abundantly higher, but the trial was 
determined prematurely [Kastrup et al. 2011]. 
Adenovirus mediated VEGF-A121 gene transfer was equally used in the REVASC trial. 
The REVASC trial recruited 67 patients randomized into treatment and control groups. 
Intramyocardial gene transfer was performed through minithoracotomy. The trial showed 
significantly improved exercise tolerance in the treatment group 26 weeks after the 
transfer although significant difference in the ST-levels during exercise test was not 
reported. In addition, there was a transient improvement in angina symptoms in VEGF- 
treated patients compared to the control group. There was no difference in the number of 
adverse events between the groups [Stewart et al. 2006]. 
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In the Euroinject I, a controlled and randomized phase II trial, 40 patients received 
percutaneuous intramyocardial injection of VEGF-A165 with naked plasmid vector. Placebo 
plasmid was used for the 40 control patients. No significant safety concerns were reported. 
Although no significant improvement in stress-induced myocardial perfusion was 
reported, some enhancement was seen in regional wall motion [Kastrup et al. 2005]. 
The Northern trial used VEGF-A121 and plasmid vector mediated gene transfer 
administed percutaneously to myocardium. A total of 93 patients participated  in  the 
study. Patients were randomized into the treatment (n=48) and control groups (n=45). 
During the 6-month follow-up no improvement in myocardial perfusion was seen in the 
treatment group compared to the control group. No safety concerns were raised during 
the trial [Stewart et al. 2009]. 
Intramyocardial VEGF-C gene transfer with naked plasmid vector failed to show 
efficacy at an interim analysis in the Genasis trial and was stopped prematurely and 
unpublished [Zachary and Morgan 2011]. 
 
2.6.2 Peripheral artery disease 
Patients with severe PAD are a potential target for proangiogenic treatment. New 
alternative treatment methods are needed for patients that are not suitable for operative 
treatment. A number of clinical VEGF trials for PAD patients have been conducted. 
In a phase I, nonrandomized clinical trial by Baumgartner et al. Nine patients with non- 
healing ischemic lower limb ulcers and/or rest pain were treated with VEGF-A165 gene 
transfer. The gene was injected into the muscles of the ischemic limb using naked plasmid 
as a delivery vector. Enhancement in collateral flow in the diseased limb or evidence of 
improved distal flow was detected in 8 patients. Furthermore, out of seven patients with 
ischemic ulcers, four were seen to experience significant healing. Transient local tissue 
oedema was seen in six patients, but no further complications or adverse events were 
reported [Baumgartner et al. 1998]. 
In randomized phase II trials VEGF-A165 has been used in two separate trials (Table 3). 
A study by Mäkinen et al. recruited a total of 54 patients with chronic limb ischemia or 
infrainguinal atherosclerotic occlusions. The patients were randomized into three groups. 
Two of the groups received VEGF-A165 with adenoviral or plasmid/liposome vector and 
the control group received ringer’s lactate. During a one-year follow-up increased 
vascularity was seen in both treatment groups. Gene transfer was feasible and well 
tolerated. In another study by Kusumanto et al. 54 diabetic patients with CLI were 
randomized into VEGF-A165 and placebo groups. Plasmid vector was used for gene 
delivery. No substantial adverse events were reported. Although there was significant 
difference regarding  haemodynamic  improvement  and ulcer  healing  to  the favour  of 
23  
VEGF- treated group, there was no difference in the number of amputations between the 
groups [Kusumanto et al. 2006]. 
The RAVE trial investigated the effects of local adenoviral VEGF-A121 gene transfer 
compared to placebo in 105 patients with intermittent claudication. No improvement in 
exercise performance was seen compared to placebo at 12 or 26 weeks. Patients in the 
treatment group experienced transient dose-dependent tissue oedema. No significant 
difference in infection markers or other safety parameters were seen between the groups 
[Rajagopalan et al. 2003]. 
 
 
Table 3 Clinical randomized phase II/III VEGF-A trials for CAD and PAD. 
 
 Trial Gene Vector n Safety Efficacy 
CAD KAT VEGF-A165 Adenovirus or 
plasmid/liposome 
103 Transient 
immunological 
Improved 
myocardial 
     responses perfusion 
 NOVA VEGF-A121 Adenovirus 17 No safety 
concerns 
No evidence of 
efficacy 
 REVASC VEGF-A121 Adenovirus 67 No safety 
concerns 
Improved 
exercise 
      tolerance 
 Euroinject I VEGF-A165 Naked plasmid 74 No safety 
concerns 
Improved 
myocardial 
      perfusion 
 NORTHERN VEGF-A165 Naked plasmid 93 No safety 
concerns 
No evidence of 
efficacy 
PAD VEGF peripheral 
vascular disease 
VEGF-A165 Adenovirus or 
plasmid/liposome 
54 No safety 
concerns 
Improvement in 
ulcer healing and 
 trial     haemodynamics 
 RAVE VEGF-A121 Adenovirus 105 Tissue oedema No evidence of 
efficacy 
 
 
2.7 SAFETY AND ETHICS OF GENE THERAPY 
 
2.7.1 Ethical aspects of gene therapy 
Gene therapy has raised many ethical questions throughout its history. Some significant 
adverse events have caused drawbacks and resulted in changes in safety regulations and 
control regarding trials [Yarborough & Sharp 2009]. However, gene therapy has shown 
evidence of efficiency and brought hope where other forms of treatment are insufficient or 
nonexistent [Hacein-Bey-Abina et al. 2010]. In treatment of such conditions, higher risks of 
adverse events can to a certain extent be tolerated. Furthermore, gene therapy is currently 
limited to alteration of somatic cells and treatment of germ line cells is not  allowed 
[Kimmelman 2008]. 
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2.7.2 Safety aspects 
Cancer 
VEGF and other growth factors are known to have an important role in tumour growth 
[Ferrara et al. 2009]. Due to mutations in growth and proliferation regulating genes, 
angiogenic growth factors become overexpressed leading to uncontrollable angiogenesis 
in malignant tumours. This creates a fragile but rapidly growing vasculature inside the 
tumour providing nutrients for fast dividing cancer cells. Tumour survival is thus 
dependent on sufficient and functioning vasculature, which has made anti-angiogenic 
therapy a major focus of interest in cancer research [Kubota 2012]. Angiogenesis is a 
complex cascade involving numerous different factors and agents that are vital for 
successful vessel growth. This permits an opportunity to interfere with several different 
steps of the signalling pathway through either suppression of pro-angiogenic gene 
expression or enhancement of anti-angiogenic gene expression [Gatson et al. 2012]. 
Preventing binding of angiogenic growth factors, such as VEGFs and FGFs, to their 
receptors has proven to be an efficient method to suppress tumour angiogenesis. Some 
anti-VEGF therapy agents have already been approved for clinical use and have 
demonstrated a good safety and efficiency profile. For instance, bevacizumab, an anti- 
VEGF antibody targeting VEGF-A expression, was accepted by the U.S. Food and Drug 
Administration (FDA) in 2004 for treatment of metastatic colon cancer. In addition, 
efficient angiogenic inhibition has been investigated. Gene therapy for glioma with 
angiognesis inhibiting angiostatin reduced angiogenesis and tumour growth in mice 
[Kirsch et al. 1998] 
Acceleration of tumour growth is one of the long-term safety concerns in growth factor 
gene therapy and the success of anti-VEGF therapy shows its importance in cancer 
development. There is a theoretical risk related to acceleration of tumour growth and 
metastasis in patients with underlying or undiagnosed malignancy [Gaffney et al. 2007]. In 
a preclinical study, where hamster ovarian cells were transfected with VEGF-A165 in vitro, 
no increase in proliferation was detected. However, in an experiment by the same group 
VEGF-expressing cells appeared with an ability to proliferate and develop local tumours 
in vivo. Tumour formation was suggested to be weak and no metastases were detected 
[Ferrara et al. 1992]. 
Another potential source of malignancy, other than the gene itself, is the vector used for 
gene delivery. As discussed earlier, retroviral vectors may cause mutagenesis in the host 
genome. This effect has been seen in two separate clinical trials treating patients with X- 
linked severe combined immunodeficiency (SCID-X1) with retroviral gene therapy. The 
patients lack an interleukin (IL)-2 receptor subunit gamma gene (IL2RG), causing a 
complete  absence  of  various  interleukins  necessary  for  immune  defence,  T-cells  and 
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natural killer (NK)-cells from birth. This condition usually leads to death in early 
childhood. Replacement of the missing gene using retroviral vector in the first trial caused 
four out of nine children to develope an acute T-cell lymphoblastic leukaemia. One of the 
cases resulted in death [Hacein-Bey-Abina et al. 2008]. For the rest of the patients, 
including the leukaemia survivors, gene therapy corrected the impaired immune system 
allowing them to conduct a normal life and development while being exposed to 
surrounding environmental pathogens [Hacein-Bey-Abina et al. 2010]. The second trial 
reported using a similar gene and vector caused one patient out of ten to develop 
leukaemia. Further analyses suggest the mutation to be a consequence of the retroviruses’ 
integration to a certain protooncogene LIM domain only 2 (LMO2). This mutation results 
in overexpression of the gene and development of leukaemia. Additionally it is possible 
that the patients had other underlying genetic abnormalities increasing the probability of 
oncogenesis [Howe et al. 2008]. 
Short-term safety follow-up studies of clinical cardiovascular VEGF-A gene therapy 
trials have not demonstrated any evidence of increased incidence of malignancies 
[Hedman et al. 2003; Kastrup et al. 2005; Henry et al 2003]. However, cancer is in most 
cases a slowly developing disease and the long-term effects of the treatment can only be 
evaluated over a period of several years. 
 
Arthritis 
Rheumatoid arthritis is an autoimmune inflammatory disease affecting one or multiple 
joints causing stiffness, pain and in advanced stage destruction of the cartilage and bone 
structure. Tumour necrosis factor (TNF)-α and different interleukins, e.g. IL-1, IL-2, IL-6, 
are known as important mediators of inflammation in arthritic lesions [Paleolog 2009]. 
Inhibition of these cytokines with monoclonal antibodies reduces efficiently disease 
activity [Maini et al. 1999; Williams et al. 2007]. 
Angiogenesis stimulating growth factors participate in the development and 
maintenance of rheumatoid arthritis. TNF-α, IL-1 IL-2 and IL-6 in combination with 
hypoxia is suggested to induce VEGF-A production, which stimulates angiogenesis in 
joints and bones [Etherington et al. 2002]. The reinforced vascular structure further 
maintains and enhances progression of pathological arthritic lesions. There is evidence 
that the inhibition of TNF-α and IL-1 by using TNF-α antibody reduces expression of 
VEGF in serum [Paleolog 2009]. In addition, VEGF inhibitors have proven to be efficient in 
the treatment of arthritis. Anti-VEGF antibody delayed the onset of the disease and 
reduced swelling and stiffness of joints in mouse models [Lu et al. 2000]. Furthermore, 
VEGFR-1 alleviated arthritis symptoms in mice [Sone et al. 2001]. Thus, systemic delivery 
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or leakage of VEGF-A outside  its target area may potentially enable development or 
progression of rheumatoid arthritis [Ylä-herttuala and Alitalo 2003]. 
 
 
Diabetic retinopathy and macular oedema 
Diabetic retinopathy is one of the most important causes of loss of vision in the western 
world [Wang et al. 2012]. Incidence of in particular type 2 diabetes, metabolic syndrome 
and cardiovascular diseases keep increase constantly all over the world, including 
developing countries. Despite significant amelioration in the treatment methods of 
diabetes and its risk factors, the complications remain a major cause of morbidity 
[Antonetti et al 2012]. It is estimated that over 30% of patients with type 1 or type 2 
diabetes develop diabetic retinopathy [Yau et al. 2012]. 
Persistent hyperglycemia and impairment of endothelial function lead to occlusions and 
hypoxia of retinal and macular cells which induces production of angiogenic factors such 
as VEGFs and PDGFs. Overexpression of growth factors activates proliferation and 
migration of ECs leading to increased vessel permeability and leakage as well as 
neovascularization. Increase in permeability causes macular oedema, thickening of the 
central fovea and eventually results in visual impairment [Gardner et al. 2012]. 
Neovascularization of the retina usually occurs near the obstructed sites where 
surrounding, perfused vessels suffering from hypoxia begin to loosen endothelial 
junctions and signalling for proliferation, migration and lumen formation are activated. 
Advanced retinal neovascularization induces vitreous haemorrhages and detachment of 
the retina [Antonetti et al. 2012]. 
Laser therapy was first introduced in 1968 as a treatment for diabetic retinopathy and it 
has been the treatment of choice for  several decades. However, in recent years anti- 
angiogenic gene therapy targeting VEGF-A signalling has proven its efficiency in the 
treatment of diabetic retinopathy in both preclinical and clinical studies. Treatment with 
protein kinase C beta inhibitors reduced macular oedema and prevented vision loss in 
human clinical trial as well as in pigs and mouse models [Ishii et al. 1996; Danis et al. 1998; 
Davis et al 2009; Viita et al. 2009]. 
Successful anti-VEGF-A therapy proves VEGF-A to have a crucial role in the 
development and maintenance of retinopathy and is thus a safety concern in VEGF-A 
gene therapy. Local gene delivery and prevention of systemic distribution can help to 
prevent these adverse effects [Markkanen et al. 2005]. 
 
 
Inflammation 
Efficient delivery vectors are an essential part of successful gene therapy. Viral vectors as 
described above, have shown to have the best transduction efficiency and the longest gene 
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expression time. However, inflammatory responses related to these vectors have raised 
concern. Although viruses used in gene therapy have been engineered replication 
deficient, they contain capsule proteins that may trigger the host immune response [Alba 
et al. 2005; Ylä-Herttuala et al. 2007]. Safety of viral vectors has improved significantly 
over the past years and also the risk of serious inflammatory reactions after gene therapy 
has been reduced [Giacca and Zacchigna 2012]. 
Perhaps the most significant drawback of gene therapy was encountered in 1999, when 
an 18-year old patient died after initiation of gene therapy for ornithine transcarbamylase 
deficiency (OTCD). The cause of death was reported to be a massive immune response 
with uncontrollable production of cytokines and other inflammatory agents as well as 
antibodies related to the use of adenoviral vector, followed by a multiple organ failure. 
The dose of adenovirus give to the patient was very high. Patients recruited in the same 
trial and treated with the same vector and gene had also shown mild signs of 
inflammation, such as fever, flu-like symptoms and elevation of infection parameters as 
well as liver transaminases [Raper et al 2003]. The initial cause  of the uncontrollable 
reaction to adenovirus remained undetermined. There had been very few clinical gene 
therapy trials prior to the OTCD trial and results gained in previous preclinical studies 
had shown promising results and a good safety profile [Wilson 2009; Stratford-Perricaudet 
et al. 1990; Nunes et al. 1999]. 
Since this incident gene therapy has been carefully re-evaluated and repeated in 
multiple animal and human studies with different types of vectors and growth factors, but 
similar fierce inflammatory reactions have not been reported [Zhang et al. 2002; Ishii et al. 
2004; Mäkinen et al. 2002; Kastrup et al. 2005]. On the other hand, mild and transient 
immune responses, such as elevation in body temperature and inflammatory parameters 
have been shown to be more common in the treatment groups receiving gene therapy via 
viral vectors in comparison to placebo or non-viral vectors [Hedman et al. 2003]. However, 
inflammatory reactions have also been reported in placebo patients, and therefore it seems 
that gene delivery procedure itself might be responsible for this as well [Stewart et al. 
2006]. 
 
 
Oedema 
VEGF induces cell proliferation and migration of ECs in hypoxic arteries. To enable this, 
existing vessel structures need to be modified and cell junctions loosened, which leads to 
increased permeability in the vessel wall and causes leakage into the extracellular space 
[Alitalo and Adams 2007]. This effect is common in particular in VEGF-A treated PAD 
patients. Trials have demonstrated an increased oedema shortly after the gene delivery at 
the treatment site. The patients have been affected by local discomfort and/or pain, but 
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symptoms have resolved within a  few days and no further complications have been 
reported [Baumgartner et al. 1998; Mäkinen et al. 2002; Isner et al 1996]. 
Tissue oedema is a far more substantial risk in VEGF-A treated CAD patients. Increased 
permeability and tissue oedema in the heart may potentially lead to pericardial effusion 
and cardiac tamponade. To reduce the risk, gene is injected in small amounts to multiple 
different sites by using the highest tolerated dosage. Despite of minimal effusion 
[Rajagopalan 2003], serious complications or tamponade have not been reported related to 
VEGF gene therapy trials. 
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3 Aims of the study 
 
Aims of this study were to investigate the following outcomes: 
 
 
1. Long-term safety of local VEGF-A gene therapy in CAD and PAD patients. 
 
 
2. Long-term efficiency and incidence of cardiovascular events in CAD and PAD patients 
following VEGF-A gene therapy. 
 
3. Procedural and short-term safety of novel AdVEGF-DΔNΔC  gene therapy in no-option 
CAD patients. 
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4 Methods 
4.1 VECTORS AND GENE TRANSFER 
 
The patients in the long-term safety studies were treated with CMV-VEGF-A165 with Ad or 
P/L vector. Adenoviruses used in the study were replication-deficient E1-E3- deleted 
viruses (serotype 5) that were produced in 293 cells by using GMP production methods. 
Viruses were tested for microbiological or endotoxin contaminations (<20 EU/dose, 
Whittaker, USA) and for absence of replication-competent viruses. To manufacture the P/L 
vectors, 1000μl DOTMA: DOPE (1:1) liposomes and 2000 μg cytomegalovirus (CMV)- 
VEGF-A165 containing plasmids were complexed and mixed with Ringer’s solution. The 
plasmids were prepared under GMP and were tested to be free of any microbiological or 
endotoxin contamination (<200 EU/dose, Whittaker, USA). The vectors were manufactured 
and provided by Ark Therapeutics Oy. 
Intracoronary application of the gene was performed by using an infusion perfusion 
catheter (Dispatch, diameter 2.5–3.5 mm, length 20 mm; Boston Scientific, MA, USA), after 
a standard PCI. Immediately after balloon dilatation the catheter was  introduced via 
femoral artery and gene transfer was performed at the site of angioplasty prior to the stent 
implantation. 
In the intramuscular gene transfer of the lower limb, a selective DSA (Siemens Polytron 
Top, Erlangen, Germany) and intravascular ultrasound (IVUS) (Sonos Intravascular, 
Hewlett–Packard, Andower, USA) were conducted prior to the PTA. After the PTA 
procedure gene transfer was done at the same site using an infusion–perfusion coil- 
balloon catheter (Dispatch, diameter 2.5–3.5 mm, length 20 mm; Boston Scientific, MA, 
USA) for infrapopliteal lesions and a channeled-balloon catheter (Remedy, Boston 
Scientific/Medi-tech) for femoropopliteal lesions. The gene transfer was done during a 10- 
minute infusion (0.5ml/minute), after which the completion angiogram was performed. 
In the short-term safety evaluation, the mature form of human VEGF-D with a flag 
tag (VEGF-D∆N∆C) with a CMV promoter was used. This VEGF-D cDNA lacks N-and C- 
terminal propeptides and contains only a central VEGF homology domain. An escalating 
dose of VEGF-D was used for the patients; The lowest titer of 1x109vpu was injected for 
the four of the first five patients, a titer of 1x1010 vpu for the next four patients and the last 
four patients received a titer of 1x1011 vpu. The three control patients did not receive any 
intramyocardial injections. 
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4.2 LONG-TERM FOLLOW-UP OF VEGF-A GENE TRANSFER 
 
4.2.1 Patient selection 
The patients for the long-term follow-up studies were initially selected according to 
specific inclusion and exclusion criteria. Briefly, all CAD patients chosen had stable CCS II 
or III angina pectoris and a minimum of 60% stenosis in one or two main coronary 
arteries. No previous coronary interventions were allowed. Exclusion criteria included 
unstable angina or MI, diabetes and previous malignancies. Women in fertile age were not 
eligible. In addition, patients with diffuse coronary lesions or complex anatomy of 
coronaries were excluded. 
Patients with PAD were considered suitable if they had an infrainguinal atherosclerotic 
stenosis suitable for revascularization. Patients with history of malignancies, type 1 
diabetes, high PSA or carcinoembryonic antigen (CEA) levels, as well as patients with 
poor co-operation, fertile women and patients under 50 were excluded [Mäkinen et al. 
2002]. Both trials were carried out at the Kuopio University Hospital. All patients in both 
studies had signed an informed consent, which also included the possibility of 
investigators to contact the patient for a long-term survey. 
 
4.2.2 Data collection and questionnaire 
The patients who had died during the follow-up were identified in both studies either 
from hospital records or the Finnish Population Register centre. All the other patients were 
interviewed by telephone or those that could not be reached were sent a questionnaire 
letter. Questionnaires were formulated for each study. Appendix 1 shows the questions 
presented for the CAD patients and questions for the PAD patients are presented in the 
Appendix 2. The standardized questions covered patients’ current state of health, 
occurrence of angina or claudication symptoms and cardiovascular procedures performed. 
The possible diagnoses of cancer, diabetes or its complications and other diseases were 
recorded. The causes of death were searched from the hospital or communal health centre 
records according to the International Classification of Diseases (ICD)-10. 
 
4.3 SHORT-TERM FOLLOW-UP OF ADVEGF-D∆N∆C GENE TRANFER 
 
4.3.1 Patient selection 
In total, 15 patients with CAD not eligible for PCI or CABG (“no-option patients”) due to 
diffuse coronary stenosis, small coronary vessels, repeated revascularizations or too high 
risk for the operation meeting the study criteria were included in the study. 
Their suitability for the study was screened according to the inclusion criteria (Table 4), 
by clinical examination, laboratory tests, electrocardiogram (ECG), transthoracal 
echocardiography  (TTE)  BET  and  chest  x-ray.  Patients  with  type  2  diabetes  mellitus 
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underwent ophtamological examination to exclude pre-existing retinopathy. Concomitant 
diseases and medication were reported and an informed consent was signed by each 
patient. The study was approved by the local Ethics Committee and the Finnish Medicines 
Agency. 
The patients were randomized 4:1 to the treatment and  control groups. The 
randomization codes were prepared prior to the start of the study. The randomization 
codes were given in successive order as each patient was recruited into the study. The 
randomization codes were covered so that only the operator performing the injections 
knew the code. The patients and other personnel were blinded for the study drug. 
 
 
4.3.2 Gene transfer 
Endocardial gene transfer was performed under fluoroscopic guidance. A 8.0 F introducer 
sheath was inserted into the right femoral vein. Transseptal puncture was performed with 
a transseptal needle 8.5 Fr AgilisTM NxT steerable introducer catheter (St Jude MedicalTM, 
St.Paul, Minnesota). After the transseptal puncture unfractionated heparin was given to 
maintain ACT between 300-350 s. An electroanatomical-mapping and injection catheter 
(NOGA©, Cordis Corp., Johnson & Johnson company, Miami Lakes, Florida) was 
introduced into the left ventricle via the transseptal route. Mapping of the left ventricular 
endocardium was done spot-by-spot to detect the ischemic areas and sites of reduced 
contraction to evaluate the optimal targets fort the gene injections. NOGA© catheter was 
used to transduce AdVEGF-D∆N∆C drug to ten different sites of the most ischemic areas. 
The injections, in depth 5-6mm, were given to ischemic myocardial areas 5-10 mm apart. 
 
 
4.3.3 Safety protocol 
One day prior to the procedure, patients were admitted to the hospital ward where ECG, 
vital signs and baseline laboratory parameters were evaluated. On the day of the 
procedure blood gas analysis and vital signs including blood pressure, heart rate and body 
temperature, were taken at the time of the gene transfer. ECG, vital signs and laboratory 
assessment were controlled 4 h after the procedure. Patients were monitored at Cardiac 
Care Unit (CCU) until the first postoperative morning and were transferred to the 
cardiology bed ward if no serious adverse events occurred during the first day. The 
patients were discharged on the second postoperative day if there were no complications. 
Laboratory and ECG assessments were repeated on the days 6 and 14. At 90 days 
patients were invited for a 3-month follow-up visit and clinical signs, laboratory 
parameters, and ECG were evaluated. To detect potential pericardial effusion, TTE was 
performed to all patients. In case of no contraindications, patients also underwent MRI at 
rest and during adenosine infusion. 
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All adverse events were classified as either serious or non-serious based on the objective 
definitions of the European Commission Enterprise and Industry Directorate [European 
commission 2006]. Adverse events were reported regardless of their causality to the study 
drug. The data was monitored according to the Good Clinical Practice (GCP) guidelines. 
 
 Table 4 Inclusion and exclusion criteria, (study III).   
 
Inclusion criteria Exclusion criteria 
- Informed consent signed 
- Age >30 but ≤ 80 years 
- Severe angina pectoris (CCS II-III) despite of 
maximal medication 
- Significant stenoses in coronary angiopraphy 
- Contraindication to coronary angioplasty or 
bypass operation (diffuse or distal stenosis, chronic 
total occlusion, vessels with difficult anatomy, 
stenosis with severe calcifications, stenosis in  
small vessels (<2,5mm)) 
- Angina pectoris or ischemic ST-depression 
(≥1mm) in the exercise test 
- LV wall >8mm detected by TTE (treatment area) 
- Women in fertile age 
- Type 1 DM or severe complicated type 2 DM, 
diabetic retinopathy 
- Clinically significant anemia (hemoglobin count 
<120mg/l in male, <110mg/l in female; 
hematocrite <0.36), leukopenia (b-leukocyte count 
< 3.0x109/l), leukocytosis (b-leukocyte count 
>12.0x109/l) or thrombocytopenia (b-thrombocyte 
count < 100x109/l) 
- Renal insufficiency (s-creatinine > 160mg/l) 
- Liver insufficiency (alanine aminotransferase and 
s-alcaline phosphatase over 2 x normal) 
- Haematuria of unknown origin 
- Severe hypertension (systolic blood pressure 
>200mmHg or diastolic blood pressure 
>110mmHg) or significant hypotension (systolic 
blood pressure <90mmHg) 
- Significant obesity (BMI >35) 
- Acute infection 
- Immunosuppressive medication 
- Significant impairment of the left ventricular 
function (EF <25% in TTE or CO< 2l in MRI) 
LV=left ventricular; TTE=transthoracal echocardiography; DM=diabetes mellitus 
 
 
 
4.4 STATISTICAL ANALYSIS 
 
 
Statistical analysis was performed by using SPSS statistical software (SPSS 17.0, Chicago, 
Illinois 60606, USA). Chi-square test was used for categorical variables and linear mixed 
models for repeated measures. P-value >0.05 was considered significant. 
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5 Results 
 
5.1 BASELINE CHARACTERISTICS AND PATIENT DEMOGRAPHICS 
 
5.1.1 VEGF-A gene therapy for coronary artery disease 
Baseline characteristics of CAD patients at the beginning of the trial are presented in Table 
5. There were no statistically significant differences between the study groups. The mean 
follow-up time was 8.1 years (6.9-9.7 years) and 89 (83%) patients were reached and 
interviewed for the study. 
 
Table 5 Baseline characteristics at randomization, (study I) 
 
 AdVEGF-A 
n=37 
P/LVEGF-A 
n=28 
Control 
n=38 
p-value 
Sex (male/female) 
Age (years) 
26/11 
58±8 
23/5 
58±7 
30/8 
56±9 
ns 
ns 
Hypertension 17 (46) 14 (50) 19 (50) ns 
Dyslipidemia 31 (84) 21 (75) 28 (74) ns 
Family history of 
CAD 
Previous 
21 (57) 
 
11 (30) 
16 (57) 
 
8 (29) 
25 (66) 
 
11 (30) 
ns 
 
ns 
myocardial 
infarction 
Previous TIA or 
 
 
3 (8) 
 
 
3 (11) 
 
 
1 (3) 
 
 
ns 
stroke 
Previous 
 
3 (8) 
 
3 (11) 
 
1 (3) 
 
ns 
peripheral ASO 
Smoker 
 
5/16 
 
4/10 
 
5/15 
 
ns 
(current/ex)     
Acetosalicylic acid 33 (89) 28 (100) 34 (89) ns 
Betablockers 26 (70) 16 (57) 22 (58) ns 
ACE inhibitors 9 (24) 5 (18) 8 (21) ns 
Statins 26 (70) 22 (79) 29 (76) ns 
Calcium channel 
antagonists 
6 (16) 5 (18) 6 (16) ns 
Nitrates 26 (70) 16 (57) 22 (58) ns 
ACE= angiotensin converting enzyme; ASO= atherosclerosis obliterans; CAD= coronary artery 
disease; TIA= transient ischemic attack; VEGF= vascular endothelial growth. n(percentage) 
 
5.1.2 VEGF-A gene therapy for peripheral artery disease 
Baseline patient characteristics at the time of randomization are presented in table 6. The 
mean follow-up time was 10 (9-12) years. The mean age of patients was 81.9 (62.6-94.7) 
years and a total of 25 (46%) patients were interviewed for the study. 
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Table 6 Baseline characteristics at randomization, (study II). 
 
 AdVEGF-A 
n=18 
P/LVEGF-A 
n=17 
Control 
n=19 
p-value 
Age (range) 70 (53-86) 74 (55-84) 73 (61-86) ns 
Men / Women 9/9 6 / 11 8/11 ns 
Symptoms 
    
Claudication 14 11 15 ns 
Critical ischemia 4 6 4 ns 
Coronary artery disease 8 9 13 ns 
Previous TIA or stroke 5 5 6 ns 
Diabetes 3 4 6 ns 
Gene transfer site 
    
Femoro-popliteal 13 14 15 ns 
Infrapopliteal 5 3 4 ns 
TIA=Transient ischemic attack. Chi-square test. The values denote n. 
 
 
5.1.3 AdVEGF-D∆N∆C gene therapy for coronary artery disease 
The baseline characteristics and demographics are presented in the table 7. All recruited 
patients were men with a mean age of 70.1 years (63-78). All patients had undergone 
CABG operation in the past and were found to have chronic occlusions or diffuse stenoses 
in the most recent angiography and suffered from CCS class II/III angina symptoms. 
Furthermore, revascularization was no longer possible. 
 
5.2. EFFICACY AND LONG-TERM EFFECTS 
 
5.2.1. VEGF-A gene therapy for coronary artery disease 
Working ability 
Changes in working ability are presented in Table 8. Working ability was assessed 6 
months after the gene transfer and at the time of the 8-year follow-up. The overall number 
of retired patients had increased in all study groups, however, inability to work due to 
CAD remained low in all groups and no significant difference was detected. The majority 
of patients had retired at the 8-year follow-up, approximately a third of the patients were 
still working and only two patients from the AdVEGF-A group were on a sick leave due to 
CAD. 
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Table 7 Baseline characteristics at randomization, (study III). 
Patient 
number 
Study group Age Sex CCS 
II/III 
Reason for ineligibility PCI CABG Type II 
diabetes 
Family HTA Dyslipidemia Smoking 
history 
1 AdVEGF-D 69 Male 3 Diffuse disease + + + + + + -
2 AdVEGF-D 66 Male 3 Diffuse disease + + + + + + + 
3 AdVEGF-D 68 Male 3 Diffuse disease + + - + + + + 
4 AdVEGF-D 75 Male 3 Chronic occlusions + + - - + + + 
5 AdVEGF-D 67 Male 3 Diffuse disease - + - + + + + 
6 AdVEGF-D 67 Male 3 Diffuse disease + + + + + + + 
7 AdVEGF-D 78 Male 3 Diffuse disease + + - + + + + 
8 AdVEGF-D 78 Male 2 Diffuse disease + + + + - + -
9 AdVEGF-D 75 Male 2 Diffuse disease + + - + + + -
10 AdVEGF-D 75 Male 3 Diffuse disease + + - + + + + 
11 AdVEGF-D 74 Male 3 Chronic occlusions - + + + - + + 
12 AdVEGF-D 63 Male 3 Diffuse disease - + + + - + -
13 Control 70 Male 3 Diffuse disease - + - + - + + 
14 Control 64 Male 2 Diffuse disease - + + + + + + 
15 Control 71 Male 3 Diffuse disease + + + + + + + 
AdVEGF-D= Adenoviral vascular endothelial growth factor-D; CCS= Canadian cardiovascular society; PCI= percutaneous coronary intervention; CABG 
coronary artery bypass grafting; HTA= arterial hypertension; + = yes, -=no. 
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Table 8 Working ability, (study I). 
 
AdVEGF-A P/LVEGF-A Control p-value 
 n=32 n=28 n=31  
At baseline 
Able to work 23 (72) 17 (66) 21 (68) ns 
Unable to work due to CAD 4 (13) 5 (19) 5 (16) ns 
Retired 5 (15) 4 (15) 5 (16) ns 
At 6 months follow-up 
Able to work 21 (66) 16 (62) 22 (71) ns 
Unable to work due to CAD 1 (3) 3 (12) 2 (6) ns 
Retired 10 (31) 7 (26) 7 (23) ns 
Long-term follow-up 
Able to work 9 (28) 8 (31) 7 (23) ns 
Unable to work due to CAD 2 (6) 0 (0) 0 (0) ns 
Retired 21 (66) 18 (69) 24 (77) ns 
Working ability at baseline and at 6-month and 8-year follow-ups. CAD= coronary artery disease; 
ns= non- significant. n (percentages). Chi-square test. 
 
Exercise tolerance 
Exercise tolerance was assessed using CCS classification. At baseline, all patients belonged 
to CCS classes II or III. Patient distribution is presented in Table 9. At 6-month follow-up 
the majority of patients (AdVEGF-A 72% vs. P/LVEGF-A85% vs. Control 84%) belonged to 
the CCS class I and only in total 4 patients to the class III. At the long-term follow-up 
distribution was somewhat similar between CCS classes I and II. Furthermore, the number 
of patients in the CCS class III had remained relatively small and in total nine patients 
belonged to this group. 
 
Table 9 Excercise tolerance, (study I). 
 
AdVEGF-A 
n=32 
P/LVEGF-A 
n=28 
Control 
n=31 
p-value 
At baseline 
CCS 2 16 (50) 13 (50) 19 (61) ns 
CCS 3 16 (50) 13 (50) 12 (39) ns 
At 6 months follow-up 
CCS 1 23 (72) 22 (85) 26 (84) ns 
CCS 2 6 (19) 4 (15) 4 (13) ns 
CCS 3 3 (9) 0 (0) 1 (3) ns 
At long-term follow-up 
CCS 1 14 (43) 12 (46) 18 (58) ns 
CCS 2 13 (41) 12 (46) 11 (35) ns 
CCS 3 5 (16) 2 (8) 2 (7) ns 
Canadian Cardiovascular Society (CCS) classification at baseline, 6 months and at 8-year 
follow-up (percentages). Chi-square test. 
 
 
Major cardiovascular events 
Cardiac death, ACS, repeated coronary interventions and stroke were considered as major 
cardiovascular adverse events (MACEs). These events were explored among the CAD 
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patients during the 8-year follow-up period. Two (2%) cardiovascular deaths occurred 
during the follow-up: In one patient the death resulted from MI and the other from 
ruptured aortic aneurysm. Thirteen patients altogether encountered an ACS. One or more 
angiographies were performed in 21 (24%) patients. PCI and CABG  operations were 
performed in eight (9%) and seven (8%) patients, respectively. The total distribution of 
MACEs were AdVEGF-A7 vs. P/LVEGF-A 4 vs. Control 9. The difference between the 
groups was non-significant. 
 
5.2.2. VEGF-A gene therapy for peripheral artery disease 
Invasive procedures and amputation 
Four patients (7%) had had an amputation of the treated limb (AdVEGF-A 0 vs. P/LVEGF- 
A 4 vs. Control 1). All of these patients were among the ones who had died and 
amputations were performed due to non-treatable CLI. In total, 11 (44%) patients had 
undergone an invasive vascular procedure. Angiography was performed in eight (4 vs. 2 
vs. 2), PTA in nine (4 vs. 2 vs. 3) surgical revascularization in two patients (1 vs. 0 vs. 1). 
The differences between the groups were statistically non-significant. 
 
Other effects 
Current PAD related symptoms and exercise tolerance according to Fontaine classification 
of the interviewed patients were additionally assessed. Exercise tolerance was compared 
to the baseline class in each group and is presented in Table 10. There were no significant 
differences between the groups or the two time points within the groups. 
 
Table 10 Exercise tolerance, (study II) 
 
Fontaine 
class 
 AdVEGF-A 
n=10 
  P/LVEGF-A 
n=8 
  Control 
n=7 
At 
randomization 
At follow-up At 
randomization 
At follow-up At 
randomization 
At follow-up 
I 0   2 0   2 0  0 
II 7   6 7   6 6  3 
III 3   0 0   0 0  3 
IV 0   2 1   0 1  1 
Severity of ischemic symptoms according to Fontaine classification at randomization and at the 10-year 
follow-up interview, n=25. p=0.43. Linear mixed models 
 
5.3 SAFETY 
 
5.3.1 Long-term safety of VEGF-A gene therapy 
Long-term safety parameters concerning the incidence of overall mortality as well as 
diabetes and cancer diagnosed after gene transfer are presented in Table 11. The mortality 
and cancer incidences are presented compared to the initial number of patients recruited 
in the trials. In comparison to CAD patients, the overall incidence of diabetes and cancer 
was higher with PAD patients, but there was no significant difference between treatment 
and control groups in either of the studies. Furthermore, the overall mortality was 
substantially higher within the PAD patients and approximately half of the patients had 
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died during the follow-up period, where as mortality in CAD follow-up was 7.5%. No 
statistical significance was seen between the treatment and control groups. In CAD 
patients, no cases of diabetic retinopathy or nephropathy were diagnosed. In PAD follow- 
up, one patient from the VEGF-p/l group had developed a diabetic retinopathy. However, 
no new cases of nephropathy were diagnosed. 
The causes of death were clarified in both studies. In CAD study, malignancy was the 
cause of death for six patients and the remaining two patients had died of rupture of aortic 
aneurysm and MI. In PAD patients, the causes of death included malignancy (AdVEGF-A 
1 vs. P/LVEGF-A 0 vs. Control 2, p=0.60), cardiac events (1 vs. 2 vs. 2, p=0.68), 
cerebrovascular events (2 vs. 0 vs. 1, p=0.75), pneumonia (0 vs. 2 vs. 1, p=0.16), PAD 
related complications (1 vs. 3 vs. 1, p=0.45), COPD 1 vs. 0 vs. 0, p=1.00), Intestinal 
haemorrhage (1 vs. 0 vs. 0, p=1.00), septic infection (1 vs. 0 vs. 1, p=1.00). For four patients 
the death certificates were not obtained and the cause of death remained unclear (0 vs. 1 
vs. 3). 
 
Table 11 Long-term safety of VEGF-A gene therapy in CAD and PAD patients, (studies I and 
II). 
 
CAD AdVEGF-A 
n=37 
P/LVEGF-A 
n=26 
Control 
n=38 
p-value 
Mortality (all cases) 3/37 (8) 2/26 (7) 3/38 (8) ns 
Cancer (all cases) 1/37 (3) 4/26 (16) 2/38 (5) ns 
Intestinal  2 (8) 1 (2.5)  
Renal  1 (4)   
Skin 1 (3)    
Brain  1 (4)   
Leukemia   1 (2.5)  
Diabetes 2/32 (6) 2/26 (8) 2/31 (6) ns 
PAD AdVEGF-A P/LVEGF-A Control  
Mortality (all cases) 8/18 (44) 8/17 (47) 10/19 (53) ns 
Cancer (all cases) 1/18 (6) 1/17 (6) 3/19 (16) ns 
Gastric   2 (10)  
Skin  1 (6)   
Leukemia 1(6)    
Lung   1(6)  
Diabetes 3/10 (30) 3/8 (38) 2/7 (29) ns 
Incidence of mortality and cancer in the total study population. Incidence of diabetes among the 
interviewed patients. Chi square test n(percentages); ns=non-significant. 
 
5.3.2 Procedural and short-term safety of AdVEGF-D∆N∆C gene therapy 
Altogether, seven SAEs were reported during the follow-up period. SAEs and related gene 
doses are presented in Table 12. There were three cases of MI or ACS (AdvVEGF-D 2 vs. 
Control 1). One of the patients was diagnosed with MI two times during the follow up. 
One control patient had an iatrogenic pericardial puncture during the procedure. TTEs 
performed on two following days showed no signs of pericardial tamponation or other 
clinically significant outcomes. New gene transfer was performed successfully three weeks 
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later. One patient in the AdVEGF-D∆N∆C  group died 10 days after the gene transfer. In the 
autopsy, MI was determined to be the cause of death. 
One control patient presented with symptoms of respiratory infection on the day of the 
procedure. Pneumonia was suspected but the confirmative diagnosis remained uncertain. 
Antibiotic treatment resolved the symptoms within five days and the patient was 
discharged on the sixth postoperative day. In addition, a patient from the AdVEGF-D∆N∆C 
group was diagnosed with pyelonephritis, which was assumed to be a cause of urinary 
tract catheter. 
Mild elevation in C-reactive protein (CRP) levels was detected in all of the patients 
during hospitalization. No similar changes were seen in blood leukocyte levels. At the 3- 
month visit, elevated PSA compared to baseline was seen in one patient in the AdVEGF- 
D∆N∆C group (3.07-9.17μg/l). Prostate biopsies showed no signs of malignancy or dysplasia. 
No elevation in the liver function parameters was found (ALT, ALP, LDH) in either of the 
groups. Clinically non-significant elevation in adenovirus antibody titers was seen at two 
weeks time in three VEGF-D∆N∆C patients. None of the patients had serious arrhythmias, 
such as ventricular or atrial tachycardias or ventricular fibrillation. No sinus arrests or II or 
III degree AV-blocks were detected during hospitalization. 
In total, three patients in the AdVEGF-D∆N∆C group were detected with mild pericardial 
effusion (3-6mm). For two of the patients effusion was seen on the second day after the 
procedure. Additional TTE control was required for one of the patients at one weeks’ time 
point when the effusion had resolved spontaneously. In the third patient, the effusion was 
seen in TTE at the 3-month follow-up visit. However, the effusion was not detected in MRI 
performed at the same visit. No further procedures or controls were required. 
 
 
Table 12 Serious adverse events (SAE) during 3-month follow-up, (study III). 
 
AdVEGF-D/Dose 
n=12 
Control 
n=3 
SAE total 4 3 
Death 1/1x1010 0 
Pneumonia susp. 0 1 
Pyelonephritis 1/1x109 0 
MI or ACS 2/1x1010* 1 
Pericardial 
puncture 
0 1 
*Both MIs occurred in the same patient. 
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6 Discussion 
 
Gene therapy has been largely investigated as a novel therapeutic approach especially to 
hereditary and genetic conditions, but it also offers potential in treatment of chronic and 
advanced cardiovascular diseases, such as CAD and PAD. VEGF has been shown to 
enhance vessel growth in ischemic tissues and thus offers new therapeutic possibilities 
[Rissanen et al. 2005]. 
Safety is one of the top priorities when investigating and introducing new therapeutic 
methods. A profound and careful evaluation of risks and adverse effects of these new 
approaches are essential before permission for wider therapeutic use can be granted. 
VEGF mediated therapy has theoretical adverse effects that may occur immediately or 
within a short period of time following the gene transfer and are mainly related to the 
gene transfer procedure or the delivery vectors. Furthermore, there are processes that may 
take significantly longer time to develop and cannot be seen until in several years time 
[Hedman et al. 2011]. 
The purpose of this work was to further clarify in particular the long-term effects of 
cardiovascular VEGF-A therapy and provide further evidence regarding some important 
safety aspects. In addition, the aim was to assess short-term safety of novel AdVEGF-D∆N∆C 
gene transfer, which was now used in human clinical trial for the first time. Since the 
short- and long-term risk factors differ in great deal, the approach and focus of interest in 
these studies were seemingly different. 
 
 
6.1 LONG-TERM SAFETY OF VEGF-A GENE THERAPY 
 
 
Short-term safety of VEGF-A gene therapy is generally well known and has been repeated 
in a number of clinical trials [Hedman et al. 2003 ;Stewart et al. 2009; Rajagopalan 2003]. 
The different isoforms of VEGF-A have been used with no significant adverse events. The 
long-term safety concerns involve among others induction of tumour growth and 
development of diabetic retinopathy where VEGF is prominently involved in the 
pathogenesis [Gaffney et al. 2007; Gardner et al. 2012]. However, until now the long-term 
safety data has been limited. In the 8- and 10- year safety follow-ups we found no 
difference in mortality or the incidences of cancer, diabetes or its complications compared 
to randomized control patients. Additionally, in comparison to general population, no 
significant difference was seen. 
Although patients with current or previously diagnosed malignancies were excluded 
from the trials, there is a theoretical risk of underlying early stage malignant process that 
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has not been diagnosed. In terms of types of cancers detected, the variation is fairly large 
and does not seem that any particular type would be overrepresented. Previously, direct 
causality between gene therapy and malignancy has been shown in trials where children 
with SCID-X1 syndrome were treated with retroviral gene therapy. In the first trial, four 
children out of nine and in the second one out of ten were diagnosed with acute T-cell 
lymphoblastic leukaemia [Hacein-Bey-Abini et al. 2010; Howe et al. 2010]. However, in 
this study no association with cancer could be seen. 
In total, eight new cases of type 2 diabetes were diagnosed in interviewed CAD patients 
(n=89) and eight in the PAD (n=25) study. This implies that diabetes has a higher incidence 
within the PAD study population than CAD patients. In addition, overall mortality was 
higher in the PAD patients. The demographics of the two study populations were 
somewhat different. In the CAD study, the mean age was lower and many of the patients 
were still working. The incidence of PAD increases after the age of 60 and the patients 
with advanced disease are thus older and affected by high  incidence of concomitant 
diseases [Tendera et al. 2011]. In fact, majority of the PAD patients were also diagnosed 
with CAD. Therefore comparison of the two studies, regarding mortality for instance, is 
difficult and the results are only observed within each study. In conclusion, VEGF-A gene 
therapy did not increase the incidence of mortality, cancer, diabetes, or diabetic 
complications. 
 
 
6.2 EFFECTS ON EXERCISE TOLERANCE AND MAJOR CARDIOVASCULAR 
EVENTS 
 
 
One of the secondary endpoints of this work was to investigate long-term efficiency and 
number of cardiovascular events and procedures among the patients. There were no 
significant differences in the number of ACSs or cardiovascular interventions in the CAD 
study. Additionally, the current exercise tolerance between the groups did not differ from 
one another. This gives the idea that gene therapy does not appear more efficient compared 
to control patients. However, it seems that all patients, including the control group, have 
fewer symptoms in comparison to baseline situation. The placebo effect in gene therapy trials 
has been claimed to be particularly strong [Lavu et al. 2011;Hedman et al. 2011] and perhaps 
the results of our study reflect this phenomenon. The number of diagnosed coronary events 
and interventions however, are more objective measures to assess efficiency. CCS 
classification is based on patient’s own subjective experience of the symptoms, and may be 
influenced by many other factors affecting exercise tolerance. This study is thus somewhat 
limited in terms of efficacy analysis. BET and cardiac imaging could provide more reliable 
data on the efficiency.  
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In the PAD study, exercise tolerance was equally assessed through a questionnaire. 
Regarding amputations, there were five patients who had had an amputation of the treated 
limb, four of which in the plasmid/liposome group. Also 44% of the patients that were 
interviewed for the study, had had a vascular intervention during the follow-up. There were 
no statistically significant differences regarding lower limb procedures. However, based on 
these results, definite conclusions regarding efficacy of the treatment were not drawn due to 
the small study population and lack of other more objective parameters. In terms of other 
clinical VEGF trials, the efficiency data is only available from a fairly short period of time 
[Kastrup et al. 2009; Stewart et al. 2009;Baumgartner et al. 1998;Kusumanto et al.2006]. As of 
yet, no data with more thorough and objective examinations in order to assess efficacy after 
several years are available [Lavu et al. 2011]. In the future, this information could be useful to 
obtain a clearer image of the true effects. 
 
It has been suggested that VEGF is involved in acceleration of atherosclerosis [Isner et al. 
2001]. From the safety point of view, the non-significant results regarding cardiovascular 
events could indicate that VEGF gene therapy does not seem to promote neo-intimal plaque 
formation or atherosclerosis. In conclusion, VEGF-A gene therapy did not seem to affect the 
number of cardiovascular events or exercise tolerance. Further objective evaluations are 
needed to evaluate the long-term efficacy. 
 
 
6.3 SHORT-TERM SAFETY OF ADVEGF-D∆N∆C THERAPY 
 
In the short-term safety evaluation of AdVEGF-D∆N∆C gene transfer the emphasis was on 
the immediate adverse events and complications related to the study drug, vector or gene 
transfer procedure. As for the study population, the first fifteen patients from total of 
thirty patients were included in the interim analysis. All patients recruited were male. The 
study population is small and definite conclusions on the gender distribution of no-option 
CAD patients cannot be made. However, it might reflect that there is a higher incidence of 
CAD in men in younger populations, and thus these patients have time to  develop chronic, 
severe occlusions over the years. Indeed, most of the patients were diagnosed with CAD 
two or more decades earlier. 
In total, seven SAEs were reported in these patients. There was only one death caused by 
acute MI in the treatment group. In addition, two other patients, one from each group, 
encountered ACS. Two of these cases occurred in the same patient. All the patients recruited 
had severe CAD and therefore very high probability of ACS. 
There was one case of suspected pneumonia in the control group and one patient in the 
treatment group was diagnosed with pyelonephritis. Inflammatory reactions have b e e n  
reported especially related to the use of viral vectors [Ylä-Herttuala et al. 2007], but no 
correlation to viral or bacterial infections has been seen. All the patients had elevation in
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body temperature and CRP level, including the control patients. This indicates that the 
catheter procedure itself has an effect on the immune system. 
Pericardial effusion was detected in three patients in the treatment group. Local tissue 
oedema has previously been reported in patients having received VEGF-A to lower limb 
muscles. Also in pig animal model myocardial effusion was detected after intramyocardial 
VEGF-D gene transfer [Rutanen et al. 2004]. Therefore increased permeability could also be 
seen after intramyocardial gene transfer in human trial. However, the effusion in all of these 
patients was minimal and caused no symptoms or need for further procedures other than 
control TTE. In two of the patients, effusion was seen within two days after the gene transfer 
where in the third patient the effusion was detected at the 3-month visit. Minimal effusion 
can be physiological and therefore it cannot be stated with certainty that gene therapy 
was the initial cause. However, in the further stages of the trial the incidence of pericardial 
effusion needs to be carefully evaluated. 
Transseptal puncture appeared to be feasible to perform and no serious arrhythmias, AV-
blocks or sinus arrests were seen during the procedure or during the hospital stay. In later 
ECG analyses there were no changes compared to the patients’ baseline rhythm. One 
iatrogenic pericardial puncture occured in one control patient, but this caused no further 
complications and the procedure was later successfully repeated. 
None of the patients was reported to have significant changes in blood pressure that 
would have required further procedures. However, NO- mediated decrease in blood 
pressure after administration of VEGF has been reported in animal studies [Liu et al. 
2001], but this effect was not seen in this study. This could be due to local delivery and 
relatively small quantity of the gene in order to cause systemic effects that the 
cardiovascular compensation mechanisms would not be able to manage. 
As discussed earlier, malignant processes take years to develop. Theoretically the presence 
of VEGF could accelerate this process. One of the patients was reported with elevated 
PSA level compared to baseline three months after the transfer. Biopsies however, showed 
no signs of dysplasia or malignancy and as the patients were all male with high age, natural 
causes for elevated PSA could also be present. 
Due to the small number of patients, no statistical analysis was performed, since a 
statistically significant finding could not have been considered reliable and could have 
potentially led to incorrect conclusions. In order to avoid any misleading results, the 
findings were reported in a descriptive form. In conclusion, AdVEGF-D∆N∆C gene therapy 
appears to be safe and feasible based on the 3-month interim follow-up. Definitive results of 
the trial will eventually bring a more profound insight on safety. 
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6.4 ETHICAL ASPECTS 
 
Gene therapy has brought hope to treating multiple diseases that are incurable, the 
treatment methods available are insufficient, or have difficult adverse effects. In particular 
genetic diseases are an interesting target for gene therapy. Ethical issues have raised a lot 
of questions throughout the history of gene therapy. The idea of changing the functions of 
human body through manipulation of the genome may seem more extreme and 
irreversible than altering effects of enzymes or transmitters by pharmacological means. It 
should be noted however, that only gene therapy targeting somatic cells is permitted. 
Manipulation of germ cells could have effects reaching over generations and is currently 
prohibited [Kimmelman 2008]. As discussed earlier, malignancies and immunological 
reactions with a proven relation to gene therapy have been reported. The public attention 
is often focused on the negative outcomes and there is a risk that the positive 
achievements are left in the background. Due to the mutagenesis and inadequate innate 
immunity, gene therapy in children with SCID-X1 syndrome, seem to hold a risk of 
leukaemia of up to 50%. However, without the treatment the children would inevitably 
die at young age and would have to live the remaining life isolated from the normal 
environment. Gene therapy, despite the high risks, can provide cure and opportunity to 
live normal life for these children. Also the chance of surviving leukaemia is relatively 
high and does not seem to influence the effect of the treatment [Hacein-Bey-Abini et al. 
2010]. In diseases such as SCID-X1 therapy can be justified even in small children unable 
to make the decision on their own. More ethical concerns might be raised in case of an 
adult patient, whose life does not depend on the treatment. 
Inflammatory reactions are an important topic in gene therapy. The causes for the 
immunological reaction and death of the young OTCD patient have since been vigorously 
explored. Wilson and Allies, the principal investigators of the particular trial, have 
attempted to repeat the event in animal models, but have failed to see similar immune 
reactions. Also other patients recruited for the particular trial did not experience as severe 
responses. Although the cause remains unclear, the investigators suggest that genetic 
predisposition to enhanced immunity or immune memory to adenovirus could trigger 
such an excessive reaction [Wilson et al. 2009]. 
In cardiovascular gene therapy, new forms of treatment are targeted at elderly patients 
that have little hope of profiting from other treatment options. In addition, other 
experimental treatment options of refractory angina, such as transmyocardial laser 
revascularization have not shown sufficient evidence of efficacy [Manchanda et al. 2011]. 
Neurostimulation is an efficient option to some patients, but it is contraindicated in 
patients that are dependent on a pacemaker or defibrillator, have anatomical limitations to 
neurostimulation  treatment  or  poor  psychological  co-operation  [de  Vries  et  al.  2007]. 
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Cardiovascular stem cell therapy is  under investigation, but has  still many unsolved 
problems and a long way to go before becoming a treatment option [Madonna and De 
Caterina 2011; Sprengers et al. 2010; Tang et al. 2010]. In the absence of effective measures 
to treat patients with refractory angina, the potential adverse events of new treatment 
forms could more easily be accepted. 
One of the challenges in the future is to continue developing vectors and delivery 
methods to further minimize known risk factors. On the other hand, all human beings are 
unique in their genetic background and unravelling the reasons why some patients react 
to the gene transfer differently than others could also provide important information. 
Whether the causes are related to genetic variation or differences in the acquired immune 
system, understanding these individual features could significantly contribute to  the 
safety as well as efficiency of gene therapy. 
49  
7 Summary 
 
 
The purpose of this doctoral work was to evaluate long-term safety of local VEGF-A gene 
transfer in patients with CAD and PAD. In addition, effects on exercise tolerance and 
incidence of major cardiovascular events and procedures were assessed. Furthermore, 
short-term safety aspects of intramyocardial AdVEGF-D∆N∆C via transseptal puncture were 
investigated. 
 
 
Based on the results the following conclusions were made: 
 
 
1. Local VEGF-A gene transfer did not increase mortality or the incidence of cancer 
or diabetes. Additionally, no significant increase in the incidence of diabetic 
retinopathy or nephropathy was detected. 
2. Local VEGF-A gene transfer did not have any significant effects on exercise 
tolerance or cardiovascular events or procedures compared to placebo. 
3. Intramyocardial AdVEGF-D∆N∆C gene transfer via transseptal puncture appears 
to be feasible and well tolerated. 
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Hyvä vastaanottaja, 
Appendix 1 1/3 
 
 
Pyydämme Teitä ystävällisesti täyttämään tämän kyselylomakkeen YMPYRÖIMÄLLÄ oikea 
vaihtoehto. 
 
1.  
a. 
b. 
Onko teillä tällä hetkellä mitään suorituskykyä rajoittavia oireita 
Ei 
Kyllä 
2. 
 
 
a. 
Jos Teillä on suorituskykyä rajoittavia oireita, onko se oire 
Rintakipu 
 b. 
c. 
d. 
Hengenahdistus 
Väsyminen 
Muu, mikä    
3. 
 
 
a. 
Jos Teillä on suorituskykyä rajoittavia oireita, tulevatko oireet 
vasta kovassa rasituksessa (esimerkiksi ylämäkeen kävellessä tai portaita noustessa) 
 b. 
c. 
d. 
jo kevyemmässä rasituksessa (esimerkiksi tasamaata kävellessä) 
levossa 
muulloin, milloin    
4. 
 
 
a. 
Oletteko tällä hetkellä 
työssä 
 b. 
c. 
d. 
e. 
f. 
sairaslomalla sepelvaltimotaudin takia 
sairaslomalla jonkin muun sairauden takia, minkä    
eläkkeellä sepelvaltimotaudin takia 
eläkkeellä jonkin muun sairauden takia, minkä    
eläkkeellä iän mukaisesti ilman sairautta 
5. 
 
 
 
 
a. 
Onko Teillä ollut viimeisen geenihoitotutkimuskäynnin jälkeen sairaalahoitoa vaatinut 
sepelvaltimotautikohtaus (äkillinen sydäninfarkti tai rintakipuoireen äkillinen 
paheneminen) 
Ei 
 b. Kyllä 
6. 
 
 
a. 
Jos Teillä on ollut sairaalahoitoa vaatinut rintakipukohtaus,  
kuinka monta kertaa    
 
b. milloin se/ne oli(vat)    
 
c. missä sairaalassa olitte hoidossa    
7. 
 
 
 
a. 
Jos olitte sairaalahoidossa sepelvaltimokohtauksen takia, tehtiinkö teille sepelvaltimoiden 
varjoainekuvaus 
Ei 
 b. Kyllä 
8. 
 
 
 
a. 
Jos olitte sairaalahoidossa sepelvaltimokohtauksen takia, tehtiinkö teille sepelvaltimoiden 
pallolaajennus ja stenttaus 
Ei 
 b. Kyllä 
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9.  Jos olitte sairaalahoidossa sepelvaltimokohtauksen takia, tehtiinkö Teille sepelvaltimoiden 
  ohitusleikkaus 
 a. Ei 
 b. Kyllä 
 
10.  Onko Teille geenihoitotutkimukseen osallistumisenne jälkeen jouduttu tekemään 
  tutkimuksia sydämen rytmihäiriöiden takia 
 a. Ei 
 b. Kyllä 
 
11. Jos Teille on jouduttu tekemään rytmihäiriötutkimuksia, milloin ja missä sairaalassa ne on 
tehty    
 
 
 
 
12. 
  
Onko Teille jouduttu asentamaan sydämen tahdistinta geenihoitotutkimukseen 
  osallistumisenne jälkeen 
 a. Ei 
 b. Kyllä 
 
13.  Oletteko joutuneet sairaalahoitoon jonkin muun kuin sepelvaltimotaudin takia 
  geenihoitotutkimukseen osallistumisen jälkeen 
 a. Ei 
 b. Kyllä 
 
14. Jos olette joutuneet sairaalahoitoon muun kuin sepelvaltimotaudin takia, minkä takia ja 
milloin ja missä sairaalassa olitte hoidossa 
 
 
 
 
 
 
 
15. 
  
Onko Teillä todettu syöpäsairautta geenihoitotutkimukseen osallistumisen jälkeen 
 a. Ei 
 b. Kyllä, mikä    
 
16. Jos Teillä on todettu syöpäsairaus geenihoitotutkimukseen osallistumisen jälkeen, missä 
sairaalassa sairauttanne on hoidettu ja milloin 
 
 
 
 
 
17. 
  
Onko Teillä todettu sokeritautia geenihoitotutkimukseen osallistumisen jälkeen 
 a. Ei 
 b. Kyllä 
 
18.  Jos Teillä on todettu diabetes geenihoitotutkimukseen osallistumisen jälkeen, onko siihen 
  liittyen todettu munuaisten vajaatoimintaa 
 a. Ei 
 b. Kyllä 
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19.  Jos Teillä on todettu diabetes geenihoitotutkimukseen osallistumisen jälkeen, onko siihen 
  liittyen todettu silmänpohjan muutoksia 
 a. Ei 
 b. Kyllä 
 
20.  Onko Teillä todettu aivoverenkiertohäiriöitä geenihoitotutkimukseen osallistumisen 
  jälkeen 
 a. Ei 
 b. Kyllä 
 
21.  Jos Teillä on todettu aivoverenkiertohäiriöitä geenihoitotutkimukseen osallistumisen 
jälkeen, missä sairaalassa sairauttanne on hoidettu ja milloin 
 
 
 
 
 
22. 
  
Onko Teillä todettu jokin muu pitkäaikaissairaus geenihoitotutkimukseen osallistumisen 
  jälkeen 
 a. Ei 
 b. Kyllä, mikä    
 
 
23. Jos Teillä on todettu jokin muu pitkäaikaissairaus geenihoitotutkimukseen osallistumisen 
jälkeen, missä sairaalassa sairauttanne on hoidettu ja milloin 
 
 
 
 
 
24. 
  
Miten koitte geenihoitotutkimukseen osallistumisen vaikuttaneen elämänlaatuunne 
 a. Ei mitenkään 
 b. Paransi vointia 
 c. Huononsi vointia 
 d. En osaa sanoa 
 
Muuta kommentoitavaa    
 
 
 
 
 
 
 
 
 
LÄMMIN KIITOS VAIVANNÄÖSTÄNNE.  HYVÄÄ JATKOA. 
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Hyvä vastaanottaja, 
pyydämme teitä ystävällisesti YMPYRÖIMÄÄN oikean, Teitä koskevan, vaihtoehdon. 
 
Oletteko tällä hetkellä työelämässä? 
a) Kyllä 
b) Eläkkeellä sairauden takia, minkä?   
 
c) Vanhuuseläkkeellä 
d) Sairauslomalla, miksi?   
 
 
Onko Teillä toimenpiteen jälkeen esiintynyt alaraajoissa kipuoireita, ns. katkokävelyä? 
a) Kyllä 
b) Ei 
 
Jos kyllä, mikä seuraavista kuvaa parhaiten suorituskykyänne tällä hetkellä? 
a) Kävelymatka yli 100m 
b) Kävelymatka alle 100m 
c) Lepokipua alaraajoissa 
d) Haavaumia tai kuolioita alaraajoissa 
 
Onko Teillä rasituksessa esiintyvää rintakipua tai hengenahdistusta? 
a) Ei 
b) Kyllä 
 
Jos kyllä, mikä seuraavista kuvaa rintakivun/hengenahdistuksen osalta suorituskykyänne parhaiten? 
a) Oireita vain kovassa rasituksessa 
b) Oireita tasamaata kävellessä 
c) Oireita levossa 
 
Jos Teillä esiintyy sekä rintakipua/hengenahdistusta sekä alaraaja-oireita, onko liikkumista 
ensimmäiseksi rajoittava oire: 
a) Hengenahdistus/rintakipu 
b) Alaraajakipu 
 
Onko Teille tehty alaraajojen varjoainetutkimusta seuranta-aikana? 
a) Ei 
b) Kyllä 
 
Jos kyllä, kumpaan alaraajaan varjoainekuvaus tehtiin? 
a) Oikeaan, montako kertaa?   
b) Vasempaan, montako kertaa?   
c) Molempiin, montako kertaa?   
 
Jos kyllä, tehtiinkö pallolaajennus? 
a) Ei 
b) Kyllä 
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Onko Teille tehty alaraajojen ohitusleikkausta seuranta-aikana? 
a) Ei 
b) Kyllä, milloin?   
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Onko Teille tehty alraaja-amputaatiota seuranta-aikana? 
a) Ei 
b) Kyllä, milloin?   
 
Onko Teillä todettu syöpää seuranta-aikana? 
a) Ei 
b) Kyllä, mikä?   
 
 
Onko Teillä todettu diabetesta seuranta-aikana? 
a) Ei 
b) Kyllä 
 
Mikäli Teillä on todettu diabetes, onko todettu jokin seuraavista liitännäissairauksista? 
a) Munaisten vajaatoiminta 
b) Verkkokalvon muutokset 
 
Onko Teillä todettu jotain muuta pitkäaikaissairautta seuranta-aikana? 
a) Ei 
b) Kyllä, mikä?   
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